In recent years, there has been growing interest in the possible use of nutraceuticals to improve and optimize dyslipidemia control and therapy. Based on the data from available studies, nutraceuticals might help patients obtain theraputic lipid goals and reduce cardiovascular residual risk. Some nutraceuticals have essential lipidlowering properties confirmed in studies; some might also have possible positive effects on nonlipid cardiovascular risk factors and have been shown to improve early markers of vascular health such as endothelial function and pulse wave velocity. However, the clinical evidence supporting the use of a single lipid-lowering nutraceutical or a combination of them is largely variable and, for many of the nutraceuticals, the evidence is very limited and, therefore, often debatable. The purpose of this position paper is to provide consensus-based recommendations for the optimal use of lipid-lowering nutraceuticals to manage dyslipidemia in patients who are still not on statin therapy, patients who are on statin or combination therapy but have not achieved lipid goals, and patients with statin intolerance. This statement is intended for physicians and other healthcare professionals engaged in the diagnosis and management of patients with lipid disorders, especially in the primary care setting.
INTRODUCTION
Cardiovascular disease and dyslipidemia: prevalence and global economic impact Cardiovascular diseases (CVDs) are the leading cause of mortality worldwide, reaching 31% of deaths in 2012. 1 In particular, atherosclerosis and ischemic heart disease are the main causes of premature death in Europe and are responsible for 42% of deaths in women and 38% of deaths in men under 75 years old. 2 The global economic impact of CVD is estimated to have been US$906 billion in 2015 and is expected to rise by 22% by 2030. 3 Cardiovascular diseases also represent the major cause of disability in developed countries. It has been estimated that their growing burden could lead to a global increase in loss of disability-adjusted life years (DALYs), from a loss of 85 million DALYs in 1990 to a loss of approximately 150 million DALYs in 2020, becoming a major nonpsychological cause of lost productivity. 4 Several risk factors contribute to the etiology and development of CVD; they are divided into those modifiable through lifestyle changes or by taking a pharmacologic treatment (eg, for hypertension, smoking, diabetes mellitus, hypercholesterolemia) and those that are not modifiable (age, male sex, and family history). 5 Elevated total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) blood concentrations are the major modifiable risk factors for coronary heart disease (CHD), whereas high concentrations of plasma high-density lipoprotein cholesterol (HDL-C) in certain conditions are considered protective. 6 Moreover, LDL-C remains a fundamental cardiovascular (CV) risk factor (and a main target of therapy) even when statins are largely used in the general population. 7 An examination of the data of 18 053 individuals aged > 20 years who participated in the National Health and Nutrition Examination Surveys in the United States from 1999 to 2006 showed that the unadjusted prevalence of hypercholesterolemia ranged from 53.2% to 56.1%. 8 Differences related to sex and race or ethnicity were observed; in particular, a lower rate of control was found among women compared with men, and lower rates of having a cholesterol check and being With the official endorsement of: told about hypercholesterolemia were reported by African Americans and Mexican Americans than whites. 8 A recent report from the American Heart Association (AHA) confirmed that in the United States only 75.7% of children and 46.6% of adults present targeted TC levels (TC < 170 mg/dL for children and < 200 mg/dL for adults, in untreated individuals). 9 The pattern is similar in other Western countries. 10, 11 The importance of treating dyslipidemia to reduce cardiovascular risk Many available clinical trials and meta-analyses have shown a relationship between a decrease in the levels of LDL-C and a reduction in the relative risk of CVD. 12 In particular, a meta-analysis of the Cholesterol Treatment Trialists' (CTT) Collaboration, based on data from 14 randomized controlled trials (RCTs), which involved 90 056 individuals, demonstrated a greater reduction in coronary and vascular events related to a greater decrease in absolute levels of LDL-C. 10 Furthermore, in a report from the CTT Collaboration that studied > 170 000 participants, it was stated that, with the cholesterol-lowering drug therapy, each further reduction of LDL-C by 1 mmol/L ($40 mg/dL) decreased by approximately one fifth the risk of revascularization, coronary artery disease, and ischemic stroke, highlighting that a reduction of LDL-C of 3.2 mmol/L (125 mg/ dL) could lead to a decrease in risk of approximately 40%-50% in the absence of an increased risk of cancer or non-CV-related death. 13 One milimole per liter is a reduction that is achievable through lifestyle improvements associated with lipid-lowering nutraceuticals. It has been estimated that every 1% reduction in LDL-C level corresponds to a reduction of the relative risk for CV events that exceeds approximately 1%. 14, 15 Lipid targets
In all adults, a fasting or nonfasting lipoprotein profile should be obtained at least every 5 years. 16 Levels of LDL-C < 100 mg/dL ($2.5 mmol/L) are associated with a low risk for CHD and are considered optimal in the absence of CVD or other risk factors. 17 Consequently, current guidelines recommend an LDL-C level of < 115 mg/dL ($3.0 mmol/L) for patients at low and moderate risk for CHD. The LDL-C treatment target is < 100 mg/dL ($2.6 mmol/L) for patients at high risk and < 70 mg/dL ($1.8 mmol/L) for patients at very high risk. 18 High-risk individuals include those with prior atherosclerotic cardiovascular disease events, including prior coronary events, transient ischemic attack, ischemic stroke, atherosclerotic peripheral artery disease (eg, ankle/brachial index < 0.90), and other atherosclerotic diseases (eg, renal atherosclerosis, atherosclerotic aortic aneurysm, and carotid plaque ! 50% stenosed). Other patient populations considered at high risk include patients with diabetes mellitus, chronic kidney disease (stage ! 3B), and those with very high levels of individual risk factors, such as familial hypercholesterolemia. 16 Elevated triglycerides (TGs) are also an independent risk factor for CVD, and their levels should be optimized in order to reduce residual CVD risk. 19 Lifestyle improvements for patients with dyslipidemia
Currently, according to the severity of dyslipidemia and the level of CV risk, treatment is based on lifestyle changes that include dietary habits and physical activity, or pharmacological therapy. 20 In fact, it is important to emphasize that nonpharmacological management should always accompany the lipid-lowering therapy. 21 Lifestyle treatment for hypercholesterolemia includes a diet low in saturated fat (< 7% of total energy), moderate or higher intensity physical activity (! 150 min/wk), and weight loss (5%-10% of body weight) for those who are overweight or obese. Exposure to active or passive tobacco smoking must be avoided as well. 22, 23 The AHA recommends a diet with a high content of fruits, vegetables, whole grains, low-fat dairy products, poultry, fish, and nuts. 24 It also recommends limiting consumption of red meat and sugary foods and beverages. Many diets fit that pattern, including the Dietary Approaches to Stop Hypertension (DASH) and the Mediterranean Diet. 25 Low-density lipoprotein cholesterol (and non-HDL-C) reductions with lifestyle improvements are most often in the range of 5%-15%, an amount that, if maintained over a long period, may result in meaningful CVD risk reduction. 5, 26, 27 For patients with hypertriglyceridemia, lifestyle interventions are key to reducing TGs. These include weight loss if overweight or obese (initially targeting a loss of 5%-10% of body weight), physical activity (! 150 min/wk of moderate or higher intensity activity), and restriction of alcohol, simple sugar, and refined carbohydrate intakes. 28 If sufficient progress is not made toward achieving atherogenic cholesterol goals, consideration may be given to the use of lipid-lowering nutraceuticals, alone or in combination with pharmacological therapy, which is indicated for patients with borderline lipid values (out of target) or who are intolerant to drugs. 29 It is, however, important to strongly emphasize that nutraceuticals cannot replace indicated lipid-lowering therapy in patients at CVD risk.
Potential role of lipid-lowering nutraceuticals in clinical practice
In recent years, nutraceuticals and functional foods have shown a role as possible supporting therapies for lowering plasma TC, LDL-C, and TGs, especially for hypercholesterolemic persons whose blood cholesterol level is moderately elevated (for instance, TC ¼ 200-240 mg/ dL or 5.2-6.2 mmol/L; LDL-C ¼ 130-160 mg/dL or 3.4-4.1 mmol/L; TGs ¼ 150-200 mg/dL or 1.7-2.3 mmol/L in patients in primary prevention for CVD) but not high enough to require pharmacological treatment. 30, 31 Based on current knowledge, nutraceuticals could exert significant lipid-lowering activity, and their intake has many advantages. First of all, the lipid-lowering effect of most nutraceuticals occurs through multiple mechanisms: the possibility that they act simultaneously on multiple stages of lipid-induced vascular damage makes them potential candidates for improving the lipid-lowering effects when used in combination with diet, drugs, or other nutraceuticals. 32 Moreover, they can have a large number of positive pleiotropic effects, including improvement of endothelial dysfunction and arterial stiffness, as well as anti-inflammatory and antioxidative properties. 33 Furthermore, a relatively large amount of epidemiological and clinical data supports the tolerability and safety of many nutraceuticals with demonstrated lipid-lowering action, including in patients intolerant to statins. 34 According to the European Atherosclerosis Society consensus document, in the last 10 years a number of observational studies have found unfavorable side effects related to statins, in particular musculoskeletal disorders (statin-associated muscle symptoms), gastrointestinal disorders, and fatigue. 35 This is particularly relevant because it is estimated that the range of people intolerant to conventional statin treatment is between 45 000 and 290 000 individuals/year 36 (complete statin intolerance is estimated at < 5%) and that statin intolerance represents one of the main reasons for statin discontinuation and nonadherence and, consequently, failure of lipidlowering treatment. [37] [38] [39] Another group of patients who might benefit from such nutraceuticals consists of very old patients (especially those aged > 75 y) or patients with sarcopenia. 40 A further category of patients who could benefit from nutraceuticals is persons already treated with statins and/or ezetimibe but who have not reached the targeted LDL-C level although they are not too far from it. The development of new powerful (and very expensive) lipid-lowering drugs will be able to fill the gap (and, in consequence, reduce the residual CV risk), but their use seems to be cost-effective only for a limited number of patients. 41 Therefore, nutraceuticals might costeffectively fill these gaps. The recent 2016 European Figure 1 Nutraceuticals acting as inhibitors of liver cholesterol synthesis. Abbreviations: HMG-CoA, 3-hydroxy-3-methylglutaryl-coenzyme A; LDL-R, low-density lipoprotein receptor; PCSK9, proprotein convertase subtilisin/kexin type 9; SREBP1, sterol regulatory element-binding protein 1; VLDL, very-low-density lipoprotein.
guidelines for dyslipidemia management consider the possibility of using some lipid-lowering nutraceuticals but do not fully consider a number of prospective and observational studies, as well as a positive meta-analysis of randomized clinical trials (RCTs), that support the possible use of a relatively large number of natural compounds. 18 Therefore, this position paper provides an up-to-date summary of the findings on the lipid-lowering effects of the most important nutraceuticals and functional foods.
Clinical evidence for lipid-lowering potential of individual nutraceuticals
Nutraceuticals with lipid-lowering effects can be divided into 3 categories according to their mechanisms of action: natural inhibitors of intestinal cholesterol absorption, inhibitors of hepatic cholesterol synthesis, and enhancers of the excretion of LDL-C (Figures 1-3) . Nevertheless, there are many functional foods/nutritional supplements with multiple or unclear mechanisms of action. Nutraceuticals described in the literature are numerous and show different levels of effectiveness and evidence of their lipid-lowering effect: the objective of this consensus is to clarify which are the major nutraceuticals with the greatest evidence and clinical efficacy. For each nutraceutical, the main mechanism of action, active principles, effective dosages, clinical evidence of effects on lipid profile, extra-lipidlowering properties (eg, endothelial function and arterial stiffness), and safety profile (if such data are available) will be briefly described.
The level of evidence and the strength of recommendations for particular lipid-lowering treatment options have been weighed and graded according to predefined scales, as outlined in Tables 1 and 2 . The experts of the writing and reviewing panels completed Declaration of Interest forms where real or potential sources of conflicts of interest might be perceived (see the end of the paper).
The approved and final version of the document is published in parallel in Archives of Medical Science (full-scope journal) and Nutrition Reviews (specialized journal) in order to maximally increase the number of readers of these important recommendations. Physicians and medical professionals of other specialties treating patients with lipid disorders are encouraged to consider this position paper in the process of evaluating the clinical status of their patients and determining and implementing medical strategies for the prevention, diagnosis, and treatment of dyslipidemia. However, the position paper does not override in any way the individual responsibility of physicians to make appropriate and accurate decisions, taking into account the condition of a given patient, in consultation with that patient and, where necessary, with the patient's guardian or caregiver. It is also the responsibility of health professionals to verify the rules and regulations applicable to drugs and devices at the time of their prescription/use.
INHIBITORS OF INTESTINAL CHOLESTEROL ABSORPTION

Plant sterols and stanols
Mechanism of action. Plant sterols, present in almost all plant sources (in particular in vegetable oils, nuts, seeds, legumes, and fat spreads), are structurally similar to cholesterol, differing in the side chain at C24 that presents a methyl or ethyl group (campesterol and B-sitosterol, respectively) or an extra double bond in C22 (stigmasterol). 42 Plant sources also contain plant stanols, such as beta-sitostanol, campestanol, and stigmastanol, that are saturated derivatives of sterols. 42 The average daily intake of plant sterols plus stanols (PS) in the common diet is low: between 150 mg/day and 450 mg/day; however, some populations, such as the Japanese or vegetarians, consume at least twice as much. 43 Efficacy. Plant sterols plus stanols reduce LDL-C by decreasing intestinal absorption of exogenous cholesterol, competing with it in the formation of solubilized micelles. 44, 45 The micelles interact with the brush border membrane and are a substrate of the Niemann-pick C1-like 1 (NPC1L1) transporter, which facilitates the transport of sterols from the intestinal lumen. However, the ATP-binding cassette protein family (ABCG5 and ABCG8) shuttles and blows out again unesterified cholesterol and the majority of sterols and stanols in the intestinal lumen. 44, 45 As a result, PS have extremely low bioavailability (0.5%-2% rapidly excreted by the liver vs 55%-60% of exogenous cholesterol); in general, plant sterols have higher bioavailability than stanols, probably due to a different arrangement in the intestinal micelles. 44, 45 This determines an increase in the intestinal lumen of the precipitate and excreted cholesterol via feces. Plant sterols plus stanols also intensify the expression of ABCA1 transporter and inhibit the acyl-CoA:cholesterol O-acyltransferase (ACAT) enzyme, reducing the amount of cholesterol absorbed from 50% to 30%. It is important to emphasize that for better therapeutic efficacy an excellent vehicle for the PS is spreadable fats, which improve their solubility, promoting dispersion and incorporation into micelles. 44, 45 The lipid-lowering effects of PS have been highlighted in several meta-analyses of RCTs. The meta-analysis of Ras et al. 44 included 41 clinical trials with 2084 individuals. The mean dose of phytosterols provided was 1.6 g/day (range, 0.3-3.2 g/d) administered through different sources (yogurt, milk, dressing, mayonnaise, and bread), and the median duration of studies was 28 days (range, 21-315 d). The metaanalysis showed not only a significant reduction of LDL-C of 0.33 mmol/L (12.8 mg/dL; À8.5%) but also an average increase in levels of sitosterol of 2.24 mmol/L (þ31%) and campesterol of 5.00 mmol/L (þ37%) compared with controls. 45 The increase in plasma levels of sitosterol and campesterol showed a dose-dependent trend: in fact, in the subgroup analysis a "high dose" of PS (range, 2.0-3.2 g/d) showed the highest levels of sitosterol and campesterol (on average 3.56 and 7.64 mmol/L, respectively). However, total PS level remained below 1% of total sterols and stanols circulating in the blood. 45 Plant sterols plus stanols could also have some impact on TGs but only in patients with high TG levels at baseline. 46 Moreover, PS supplementation has a mild but significant improving effect on high-sensitivity C-reactive protein (hs-CRP). 47 The lipid-lowering effect of PS is dose dependent and proportional up to the attainment of a plateau (reached at approximately 3 g/d of PS, achieving an average effect on LDL-C of À12%) due to saturation of the uptake of cholesterol and transport process. At doses up to 3 g/day, there were no differences in efficacy on cholesterolemia between stanols and sterols. 48 Another meta-analysis of RCTs showed that 2 of the best fat carriers for PS are rapeseed or canola because of their high content of monounsaturated fatty acids and n-3, which enhances the functionality of PS. 45 The effect of PS on endothelial function has been recently investigated in 2 large RCTs that furnished conflicting results. 49, 50 Safety. In conclusion, PS produce a mean reduction of LDL-C by 8%-12% in participants with hypercholesterolemia. Plant sterols plus stanols have also shown a high safety profile in the middle term; however, data for treatment longer than 2 years are still not available. 44, 49 
Soluble fibers
Dietary fibers is a term commonly used for a variety of substances of vegetable origin resistant to enzymatic digestion in the gastrointestinal tract. Generally, they are divided according to their solubility into soluble and insoluble fibers. 51 For the last several years, some studies have focused on the lipid-lowering properties of soluble fibers, including pectin, guar gum, mucilage, oats, and psyllium, showing a reduction in TC and LDL-C. 50, 52 The lipid-lowering mechanisms of action of soluble fibers are different, including prolonged gastric emptying time, an increase of satiety, the inhibition of hepatic cholesterol synthesis, and an increase of fecal excretion of cholesterol and bile salts. 51 The reduction of cholesterol obtained by soluble fibers described in the literature is variable and dependent on the type of fiber, doses, persons treated, study size, and different diets: the effective range of the reduction of TC varies from 0% to 18% for oat-based fibers, 3% to 17% for psyllium, 5% to 16% for pectin, and 4% to 17% for guar gum. 27 
b-Glucan
Mechanism of action. b-glucan is a soluble fiber derived from the walls of different plant cells, bacteria, algae, fungi, and yeasts. b-glucan has high viscosity, which confers lipid-lowering action. 32 Efficacy. A meta-analysis of 17 RCTs with 916 patients showed that b-glucan consumption in a hypercholesterolemic population significantly reduced LDL-C (À0.21 mmol/L [8.1 mg/dL]; 95%CI, À0.27 to À0.14; P < 0.00001). However, there were no significant differences in HDL-C and TGs. No adverse effects were reported among the eligible trials. 53 In 2010 the European Food Safety Authority (EFSA) confirmed that oat b-glucan is able to reduce plasmatic cholesterol levels; however, at least 3 g/day of b-glucan is necessary. 54 According to the American and European guidelines for the management of dyslipidemia, the consumption of 5-15 g/day (European guidelines) or 10-25 g/day (US guidelines) of soluble fibers derived from oat rich in bglucan can essentially reduce the levels of cholesterol in the blood. 55, 56 Finally, the study of Tabesh et al. 57 showed that the consumption of b-glucan for 4 weeks in 60 patients with hypercholesterolemia increased the serum levels of nitric oxide (P ¼ 0.017) but had no effect on flow-mediated dilatation (FMD).
Safety. Due to the lack of enough data it seems to be important to evaluate the efficacy and safety of administration of b-glucan in the long-term follow-up as well as to clarify whether there is a dose-response relationship and whether it can decrease the CV risk.
Psyllium
Mechanism of action. Psyllium is a natural source of concentrated fibers derived from the husks of blonde psyllium seed. The mechanisms of action of psyllium are similar to those of other fibers, including increased excretion of bile acids (stimulating 7 -a-hydroxylase), reduced absorption of intestinal cholesterol, and a reduction of hepatic cholesterol synthesis (via the shortchain fatty acid byproducts of fiber fermentation). 58 Efficacy. A meta-analysis of 21 studies, which enrolled a total of 1030 and 687 participants receiving psyllium or placebo, respectively, concluded that, compared with placebo, consumption of psyllium lowered serum LDL-C by 0.278 mmol/L (10.8 mg/dL; 95%CI, 0.213-0.312 mmol/L). With random-effect meta-regression, a significant dose-response relationship was found between doses (range, 3-20.4 g/d) and total cholesterol or LDL-C changes. Following an average intake of psyllium of 10 g/day, an average reduction of LDL-C of 7% was observed. 59 Moreover, psyllium showed good efficacy also in children and adolescents, with the percentage of LDL-C reduction similar to the one in adults. 60 The reduction of cholesterol was more pronounced in participants in the United States with hypercholesterolemia who consumed a high-fat diet. 61 Psyllium supplementation might also have a positive effect on glucose metabolism-related parameters. 62 However, psyllium has shown no significant effects on vascular function. 63 Safety. All available clinical trials and meta-analyses confirm the good safety profile of psyllium (at doses up to 20 g/d) that is documented by the Food and Drug Administration (FDA), the Select Committee on Generally Recognized Safe Substances, and the Expert Panel from the Life Sciences Research Office. However, in some cases, minor gastrointestinal side effects were reported (especially with micronized fibers) that might slightly reduce the adherence to this nutraceutical. 64 Glucomannan Mechanism of action. Glucomannan is a particular soluble fiber, widely used in the Orient for over a thousand years, derived from Amorphophallus konjac, commonly referred to as konjac root, and available as a nutraceutical in different forms such as capsules, tablets, and sachets. Structurally glucomannan is a polysaccharide constituted of glucose and mannose (ratio, 1:1.6) bound through b-1,4-glycosidic bonds. 32 Unlike other fibers, glucomannan does not act by binding bile acids, but it seems to reduce the absorption of cholesterol in the jejunum and the absorption of bile acids in the ileum, yielding improvements in apolipoprotein B (ApoB) and plasma LDL-C levels. It also increases the activity of 7 -a-hydroxylase, an enzyme that converts cholesterol into bile acids. 65 Efficacy. A recent meta-analysis that included 14 RCTs with 531 patients concluded that the use of glucomannan (at doses ranging between 1.24 and 15.1 g/d) significantly reduces LDL-C and TGs, respectively, by À0.41 mmol/L (15.9 mg/dL) and À0.13 mmol/L (11.5 mg/dL) (P < 0.05 for both) compared with placebo. The reduction of serum triglycerides is a peculiarity of glucomannan, probably due to its high viscosity and its ability to interact with the hepatic cholesterol and lipoprotein metabolism, but not of other soluble fibers, which have only a very modest action on triglyceride levels. 66 Data on weight reduction are controversial; in general, it can be said that glucomannan is able to promote the maintenance of weight, and in some cases (with at least 5.2 wk of treatment) it can cause a small reduction in weight (according to some metaanalyses, significant; according to others, not), although only less than 1 kg. 67 Treatment with glucomannan has also given positive results in children with primary hyperlipidemia. Guardamagna et al. conducted a study with 36 dyslipidemic children (6-15 y old) treated with glucomannan twice daily for 8 weeks. The results showed a significant reduction in LDL-C (À7.3%; P ¼ 0.008) and non-HDL-C (À7.2%; P ¼ 0.002) compared with placebo. These effects had a more pronounced trend in females than in males. 68 The same correlation was also found in the study of Martino et al., where 40 children were treated with 2-3 g/day of glucomannan and benefited by a reduction of LDL-C of 30% in females and 9% in males (P ¼ 0.046). This sex-dependent effect was also observed with other soluble fibers, and it would seem to be caused by the interaction between sex hormones and lipid metabolism; nevertheless, further corroboration is necessary. 69 The abovementioned results have been confirmed in a further study by the same authors on a larger sample of 120 hypercholesterolemic children. 70 Safety. The intake of glucomannan may interfere with the absorption of certain drugs, in particular lipophilic drugs/nutraceuticals: for example, glucomannan could reduce the absorption of vitamin E, calcium, and other minerals, whereas it does not hinder the absorption of water-soluble vitamins. Therefore it is recommended to take the medication 1 hour before or at least 4 hours after taking glucomannan. 32 In general, the consumption of glucomannan does not cause serious side effects; most side effects are gastrointestinal, such as diarrhea, flatulence, and abdominal discomfort.
Chitosan
Mechanism of action. Chitosan is a nonfiber lipidlowering agent isolated from shellfish and sea crustaceans that inhibits cholesterol absorption in the bowel.
Efficacy.
A meta-analysis of 6 RCTs that included 416 patients with hypercholesterolemia concluded that it has a significant effect on TC (À0.3 mmol/L [11.6 mg/ dL]; P ¼ 0.002) but not on LDL-C, HDL-C, or TGs. 71 Because other trials have yielded conflicting results with a significant reduction of all lipid parameters, 72 further studies are necessary to have clear data on efficacy both in the short and long term of consumption. However, chitosan supplementation is associated with mild weight loss 73 and an improvement in insulin resistance-related parameters. 74 Safety. Transient side effects such as abdominal pain, diarrhea, vomiting, and constipation occur in rare cases at doses ranging between 1 and 6 g/day (indicative daily doses). 75 Probiotics Mechanism of action. Probiotics are defined as vital microorganisms that confer health benefits to the host when taken in adequate amounts. The consumption of probiotics is considered safe and free of serious side effects. 76 In recent years, some clinical studies have supported the hypothesis of a possible clinical use of certain strains of microorganisms as cholesterol-lowering agents. Nevertheless, it is still very difficult to draw firm conclusions due to the great heterogeneity of the studies in duration, type of probiotic strains used, dosage, clinical characteristics of the participants, and dosage form/ vehicle. The mechanisms of action whereby probiotics reduce cholesterolemia are still unclear. Among the proposed mechanisms, it is possible that probiotics interact with the intestinal cholesterol, binding or incorporating it into the cell membrane. 77 Lactobacillus acidophilus and Lactobacillus bulgaricus contain some enzymes (cholesterol dehydrogenase/isomerase) able to catalyze the transformation of cholesterol into cholest-4-en-3-one, an intermediate cofactor in the conversion of cholesterol to coprosterol or coprostanol, which are directly excreted in the feces. 78 Other probiotics reduce the enterohepatic circulation of bile salts through activity of bile salt hydrolase (BSH) enzymes; there is a mechanism based on the ability of some lactobacilli and bifidobacteria to deconjugate bile acids enzymatically, increasing their excretion rates and attracting greater mobilization of systemic cholesterol to the liver for de novo synthesis of bile salts. 79 Finally, some probiotics may alter bowel pH, the formation of micelles, the transport pathways of cholesterol and/or lipoprotein (such as NPC1L1 gene expression), and cholesteryl esters. 80 These mechanisms are hypothetical, so further well-designed studies are required to elucidate which of these have a greater influence on cholesterol reduction. Efficacy. A recent meta-analysis included 30 RCTs to investigate the effect of probiotics on TC, HDL-C, and TGs and 27 RCTs to investigate the effect of probiotics on LDL-C. The most studied probiotic strains were L. acidophilus, L. acidophilus plus Bifidobacterium lactis, and Lactobacillus plantarum. The mean duration of the studies was 7 weeks, and the studies involved normo-(TC < 200 mg/dL) or hypercholesterolemic participants. The pooled mean net change in LDL-C was À0.19 mmol/L (7.35 mg/dL; P < 0.01) compared with controls. Triglycerides and HDL-C did not change significantly compared with the control groups. In a subgroup analysis, the maximum reduction in LDL-C was obtained in studies that included hypercholesterolemic participants who had higher levels of cholesterol at baseline. 81 Based on available data, it seems that the best results were obtained with Lactobacillus strains. One possible explanation might be the adaptation of Lactobacillus species (in particular L. acidophilus and L. plantarum) that allows them to survive in acid and bile environments and easily colonize the gastrointestinal tract. 82 A stronger cholesterol-lowering effect of Lactobacillus was confirmed in the meta-analysis of RCTs by Shimizu et al., 83 where the most promising results were obtained after a treatment period of > 4 weeks, but they could not prove any significant improvements in either HDL-C or TGs. More studies are needed to strictly define the types of people who would benefit most, the probiotic strains, the dosage forms or the administration vehicles of the strains (researching any interference or pleiotropic action due to the vehicle), the duration of the treatment, the dosages, and the cholesterol-lowering mechanisms. To date, the clinical findings are still not sufficient to recommend probiotics as a nonpharmacologic alternative to improve the lipid profile.
Safety. Probiotics are considered to be generally very safe, and side effects are rare. The report released by the Agency for Healthcare Research and Quality (2011) concluded that, although the existing probiotic clinical trials reveal no evidence of increased risk, there are not enough data to answer questions on the safety of probiotics in intervention studies with confidence. 84 
INHIBITORS OF LIVER CHOLESTEROL SYNTHESIS
Red yeast rice extract
Mechanism of action. Red yeast rice (RYR) is a nutraceutical obtained by the fermentation of a particular yeast (in general Monascus purpureus, Monascus pilosus, Monascus floridanus, or Monascus ruber) in rice (Oryza sativa) that gives the typical red coloration to the rice for the presence of pigments produced by the secondary fermentative metabolism. Red yeast rice contains sugars (25%-73%, in particular starch), proteins (14%-31%), water (2%-7%), fatty acids (1%-5%), pigments (such as rubropunctamine, monascorubramine, rubropunctatin, monascorubrin, monascin, ankaflavin), sterols, isoflavones, and polyketides. 85 The yeast during the fermentation process enriches the rice with a complex of substances with important lipid-lowering activities, including polyketides such as monacolins. Usually the food supplements derived from RYR contain a concentration of monacolins of up to 1.9%. 86 Based on the conditions of fermentation and the yeast strain used, today several types of monacolins have been identified (compactin, monacolins M, L, J, X), including the subtype monacolin K (MonK), which is structurally identical to lovastatin. The main cholesterol-lowering putative mechanism of action of RYR is caused by a reversible inhibitory action on 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase (the key enzyme in endogenous cholesterol synthesis).
Despite having the same structure, MonK and lovastatin pharmacokinetic profiles and bioavailability can be different: in fact, if lovastatin is administered in conventional pharmaceutical form as a single active ingredient (31% of bioavailability in humans), MonK is only one of the components of the RYR that can interact to change the typical pharmacokinetic profile of lovastatin. Another important aspect that emphasizes the possible pharmacokinetic and clinical efficacy differences regards the chemical structure of MonK: the ratio of lactone to acid strongly varies, the acid being the active one and much better absorbed. The acid form can range from 5% to 100% of the total MonK (difficult to estimate), greatly influencing the bioavailability of the molecule. The lactone ring opening can occur following metabolism in alkaline conditions or enzymatically by the small intestine and liver cytochrome P450 (CYP) 3 A family. 87, 88 Efficacy. The lipid-lowering efficacy of RYR has been confirmed by some meta-analyses of RCTs; the most recent one included 20 trials evaluating the efficacy and safety profile of this nutraceutical. The results showed that (after 2-24 months) RYR reduced LDL-C on average by 1.02 mmol/L (range, À1.20 to À0.83; 39.4 mg/dL) compared with placebo, which was not different from moderate-intensity statins (40 mg of pravastatin, 10 mg of simvastatin, 20 mg of lovastatin; 0.003 mmol/L; range, À0.36 to 0.41; 0.12 mg/dL). A small increase of HDL-C (0.007 mmol/L; range, 0.03-0.11; 0.3 mg/dL) and decrease of TGs (À0.26 mmol/L; range, À0.35 to À0.17; 23 mg/dL) compared with placebo was observed. The doses of RYR used were different and varied from 1200 mg/day to 4800 mg/day containing from 4.8 mg to 24 mg of MonK. Concerning the safety profile, the incidence of cases of liver abnormalities and kidney injury was between 0% and 5% in both groups (RYR and control). In addition, the incidence of developing muscular symptoms was lower in RYR groups (0%-23.8%) compared with control groups (0%-36%). There were no cases of rhabdomyolysis or myopathy with creatine kinase levels increased > 10 times the upper limit. 89 In fact it has been clearly shown that the safety profile of RYR is similar to that of lowdose statins. 90 These data consolidate the results obtained in a previous Chinese meta-analysis that included 93 trials with a total of 9625 participants. 91 The reason why the reduction of serum cholesterol is comparable between RYR and statin groups (at doses many times higher than the corresponding MonK) is still unclear. It is possible that nonstatin components of RYR (such as polyunsaturated fatty acids) exert pleiotropic actions on reducing cholesterol, thus reaching the same values as the groups treated with singlecomponent statins. 84 Furthermore, the tolerance of RYR is usually greater than that of statin treatment. The reason is again not clear, but it could be explained by the fact that the daily dose of MonK in dietary supplements is usually much lower than that of statins.
Red yeast rice also improves endothelial function in humans. In a clinical trial involving 50 patients with CHD treated with 1200 mg/day of RYR or placebo for a period of 6 weeks and following a meal with high fat intake (50 g), the levels of hs-CRP and FMD (at 0 and 4 h) and the lipid parameters were monitored. The results showed that the group treated with RYR at the end of the 6-week follow-up obtained a reduction of hs-CRP and the area under the curve of TGs (P < 0.001 for each), in addition to an improvement of postprandial and preprandial FMD (P < 0.001). There were no significant changes in serum lipids and FMD in the placebo group. 92 Red yeast rice use is a rare example of a nutraceutical studied to evaluate its effects on CV outcomes. Red yeast rice supplementation has shown relevant efficacy in reducing CVD risk in adult and elderly patients in secondary prevention. 91 In a large trial involving 66 hospitals in China, 1445 patients (aged between 65 and 75 y) with a history of myocardial infarction were randomized to 2 groups (placebo vs RYR) and followed for a mean of 4 years. Red yeast rice supplementation showed a reduction in the risk of CHD (À31.0%; P ¼ 0.04), all-cause mortality (À31.9%; P ¼ 0.01), stroke (À44.1%; P ¼ 0.04), the need for coronary artery bypass graft or a percutaneous coronary intervention (PCI) (À48.6%; P ¼ 0.07), and malignancies (À51.4%; P ¼ 0.03). It was also estimated that following RYR treatment for 4 years, the number needed to treat to prevent 1 coronary event, 1 coronary death, and 1 mortality due to all causes in elderly patients were, respectively, 18, 33, and 23. In adults, however, these numbers were 23, 82, and 51. Side effects were not significantly different between the groups. 91 Safety. Inhibitors or inducers of CYP450 may cause alterations of plasma concentrations of MonK. In fact, the concomitant use of some nutraceuticals (such as grapefruit juice), 93 food, or drugs (cyclosporine, niacin, fibrates, coumarin, verapamil, antifungals, macrolides, nefazodone, human immunodeficiency virus protease inhibitors 94 ), that are CYP450 inhibitors may increase the risk of myotoxic side effects and in some rare cases cause rhabdomyolysis. 95 Although the chronic administration of monacolins could be responsible for mild to moderately severe side effects, it is usually well tolerated. However, serious attention must be paid to citrinin, a mycotoxin metabolite derived from the fermentation of Monascus. 96 The chronic ingestion of citrinin is nephrotoxic in various animal species, gradually leading to hyperplasia of the renal tubular epithelium, renal adenomas, and in some cases to renal tumors (at a dose of 50 mg/kg body weight [b.w.] causing tumors in 100% of the animals tested). Moreover, citrinin induces reproductive toxicity, malformations, and proven embryo toxicity in vitro and in vivo. [97] [98] [99] The EFSA has established 0.2 mg/kg b.w. per day as the highest quantity of citrinin that can be taken by humans with no nephrotoxic effects. 100 However, at these doses genotoxic and carcinogenic effects are not excluded. In the market RYR supplements with levels of citrinin exceeding 114 mg/capsule were detected, and for 4 capsules/day (recommended dosage) the mean was 456 mg/day of citrinin, which is well above the level of 20 mg/kg b.w. per day suggested by the EFSA. 85 In summary, the administration of RYR can be recommended because of its effects on LDL-C in patients with moderately elevated cholesterol, especially in primary prevention. On the basis of the available evidence, the EFSA has expressed a scientific opinion on the substantiation of health claims about the relationship between administration of RYR and the maintenance of plasma LDL-C levels-the relationship is possible using a dose of RYR that contains 10 mg of MonK (maximum daily dose in Europe as dietary supplement). 101 However, some National Regulatory Agencies in Europe have recently suggested using lower dosages of MonK for safety purposes. Moreover, specific attention has to be given when full-dosed RYR is administered in previously statin-intolerant patients.
Garlic (Allium sativum)
Mechanism of action. Garlic (Allium sativum) is a nutraceutical known for its multiple health properties. One of the most important molecules present in garlic is allicin (diallyl thiosulfinate), which is produced from the nonproteinogenic amino acid alliin (S-allyl cysteine sulfoxide) in a reaction catalyzed by alliinase. 102 Allicin could be one of the chemical entities responsible for the lipid-lowering mechanism of action of garlic. In fact, it seems to be an inhibitor of HMG-CoA reductase, squalene-monooxygenase, and acetyl-CoA synthetase enzymes. Allicin contains a thiol group, so it is also possible that it reacts with nonacetylated-CoA directly, reducing acetyl-CoA available for endogenous synthesis of cholesterol. 101 Other suggested mechanisms of action of garlic are blocking the absorption of dietary cholesterol and fatty acids and increasing excretion of bile acids. However, further studies are necessary to finally confirm these effects and the molecules responsible for these possible lipid-lowering activities. 103 Efficacy. In a meta-analysis of 39 RCTs enrolling 2298 mild-to-moderate hypercholesterolemic participants, the consumption of garlic extracts for at least 2 months showed a reduction of LDL-C (À0.23 mmol/L [9 mg/dL], more evident in individuals with TC < 5.17 mmol/L [200 mg/dL] at baseline). 104 The same author highlighted the beneficial effect on blood pressure of garlic, 105 and Jung et al. 106 underlined that it is able to reduce ApoB and increase the LDL/Apo B ratio. According to a recent meta-analysis of RCTs, garlic seems not to have any effect on lipoprotein (a) (Lp(a)) level. 107 Finally, garlic might exert significant antiplatelet activity in humans. 108 In conclusion, garlic at a dose of 6 g/day (depending on the percentage of allicin) could be useful in the management of mild cholesterolemia, probably more for the parallel antihypertensive and antiplatelet effect than for the lipidlowering one. The high doses required and the common aftertaste could limit the long-term compliance with treatment.
Safety. Side effects are usually minimal (mostly gastrointestinal), and the extracts are well tolerated. 102 Pantethine Mechanism of action. Pantethine, a dimeric form of pantetheine produced from pantothenic acid (vitamin B5) by the addition of cysteamine, has been widely tested for lipid-lowering activity. In vitro it inhibits fatty acid synthesis and HMG-CoA reductase. 109, 110 Several human trials have confirmed these effects in humans. 111, 112 Efficacy. Recently a 16-week, triple-blinded RCT carried out on 120 participants with low-to-moderate CVD risk was published. 113 The authors showed that, in comparison with placebo, 600-900 mg/day of pantethine demonstrated significant (P < 0.005) and sustained reductions (from baseline to week 16) in TC (À3%; 0.16 mmol/L [6 mg/ dL]), LDL-C (À4%; 0.10 mmol/L [4 mg/dL]), and ApoB (À5%; 0.0001 mmol/L [4 mg/dL]). The data suggest that pantethine supplementation for 16 weeks (600 mg/d for weeks 1-8, then 900 mg/d for weeks 9-16) is safe and significantly lowers TC and LDL-C (although with relatively limited clinical relevance) over and above the effect of therapeutic lifestyle changes or diet alone. 112 In a further 16-week, triple-blinded RCT carried out on mildly hypercholesterolemic participants, 600-900 mg/day of pantethine reduced LDL-C level by 11%. 114 Safety. The tolerability of pantethine is overall high, with acceptable safety confirmed also in children 115 117 In particular, the 3-hydroxy-3-methyl-glutaryl flavanone-enriched fraction (HMGF: brutieridin, melitidin, and HMGneoeriocitrin) has been extracted from the bergamot peel; they act as statins by inhibiting HMG-CoA reductase and ACAT, reducing the formation of cholesterol esters and limiting the transport of cholesterol in the blood. Bergamot also contains naringin: like neoeriocitrin, melitidin, and rutin, it inhibits the oxidation of LDL-C, initiates adenosine-monophosphate-kinase (AMPK), and has shown scavenging activity, suggesting a possible preventive antiatherosclerotic mechanism. It is also possible that bergamot increases the fecal excretion of cholesterol, reducing the intestinal absorption and increasing the turnover and excretion of bile acids. 118, 119 Efficacy. Clinical studies on the lipid-lowering properties of bergamot are still very few. Moreover, the groups treated with BPF (either alone or in combination) experienced a reduction of some biomarkers of vascular oxidative damage, including malonyldialdehyde (one of the major aldehydes formed during lipid peroxidation) and oxidized LDLs. 120 The same author evaluated the effects of bergamot (1 300 mg/d) in 107 patients (divided into 2 groups) with metabolic syndrome (MetS) and nonalcoholic fatty liver disease (NAFLD) during 120 consecutive days. They found that the treated group experienced a marked reduction of small dense LDL (sdLDL) and TGs and increased HDL-C levels compared with placebo. Moreover, this was accompanied by a significant reduction of serum glucose, transaminases, gammaglutamyl-transferase, and inflammatory biomarkers such as hs-CRP and tumor necrosis factor-a (TNF-a). 121 Moreover, the amount of atherogenic sdLDL significantly decreased (À35%), whereas large buoyant LDLs increased (þ38%; both P < 0.05) compared with baseline levels. These data are important and emphasize the potential use of bergamot for reducing CVD risk, knowing that elevated levels of sdLDL-C associated with NAFLD are associated with an increased CV risk. 122 showed dose-dependent lipid-lowering action of bergamot (groups A and B, respectively, LDL-C: À24.1% and À30.6%, TGs: À28.2% and À37.9%, HDL-C: þ22.3% and þ40.1%; P < 0.001 for all) compared with baseline. Group C (placebo) did not show significant reductions in serum cholesterol. Group D showed a reduction of LDL-C and TGs (À25.0% and À27.6%, respectively; P < 0.001 for all), without any side effects. 123 In summary, the evidence indicates that bergamot has lipid-lowering effects, both quantitative and qualitative, especially by reducing the levels of sdLDL and TGs and significantly increasing HDL-C levels. This suggests a potential use of bergamot in hypercholesterolemic and/or hypertriglyceridemic patients with NAFLD and MetS who are intolerant to statins. The main limitation of the evidence on bergamot efficacy is related to the fact that the greater part of the clinical literature has been provided by a single research unit and not confirmed elsewhere. Moreover, data on vascular parameters such as endothelial function and arterial stiffness are not available yet.
Safety. Clinical studies conducted to date with dosages between 500 and 1 500 mg/day showed a good safety profile, with no side effects detected. 124 Policosanols have demonstrated inhibitory action on HMG-CoA reductase and on bile acid absorption, in addition to an activating effect on AMPK (increase of fatty acid b-oxidation). 125 Efficacy. In recent years several clinical studies have suggested a reducing action of this nutraceutical on lipid profile, but the results are often nonsignificant.
The study by Berthold et al. showed that the administration of policosanols in hypercholesterolemic patients does not statistically improve the levels of TC, TGs, HDL-C, and LDL-C. This trial included 143 participants divided into 5 groups, each treated with 10, 20, 40, or 80 mg of policosanols or placebo. Nobody in any group at the end of the study (12 wk) showed a reduction of > 10% in LDL-C. 126 These data were confirmed by the study of Backes et al., 127 where policosanols did not significantly change the lipid profile of hypercholesterolemic participants in either of the 2 treatment groups (treated with policosanol or policosanol in addition to statin therapy) or placebo compared with the control. Neither policosanols from rice nor wheat germ showed any significant effect on LDL-C, HDL-C, TGs, oxLDL (oxidized low-density lipoproteins), ApoB, Lp(a), homocysteine, CRP, fibrinogen, or blood coagulation factors. 128, 129 There are several clinical studies demonstrating the efficacy of combinations containing policosanol in association with other nutraceuticals (such as fermented red rice, berberine), but the role of the lipid-lowering effect of policosanol in these combinations is not clear. Based on all these data, policosanol should not be recommended in clinical practice until new well-designed studies are performed that definitively clarify its lipid-lowering potential effect.
Safety. The tolerability of policosanols is usually very good. 131, 132 Berberine also has some secondary mechanisms of action; recent studies have emphasized that it reduces the intestinal absorption of cholesterol, increasing the fecal excretion and promoting the hepatic cholesterol turnover and the formation of bile acids. 133 Moreover, BBR is an activator of AMPK, which determines an increase of fatty acid oxidation and a reduction of the expression of lipogenic genes. Finally, it is an effective inhibitor of nicotinamide adenine dinucleotide phosphate (NADPH) oxidasemediated oxidative stress. 134, 135 It is important to emphasize that BBR is just one of the alkaloids present in the plants; it is therefore possible that some pleiotropic activities (such as antioxidant, anti-inflammatory, insulin sensitizer) might be due to some other substances and not only BBR. In Berberis vulgaris alone, in addition to berberine, the following compounds have been have been identified: alkaloids -acanthine, bargustanine, berbamine, berberrubine, beriambine, bervuleine, columbamine, jatrorrhizine, lambertine, magnoflorine, palmatine, thaliemidine; vitamins -ascorbic acid, vitamin K, beta-carotene; and tannins, flavonoids and flavanols, triterpenes, and coumarins. 136 The bioavailability of BBR is < 1%. This is due to the poor intestinal absorption (56%), caused by a self-particulate aggregation that reduces the solubility in the gastrointestinal tract, to the low permeability of the molecule (Biopharmaceutical Classification System class III), and to the intestinal and liver first-pass metabolism (43.5% and 0.14%, respectively). 135 The effect of the intestinal first pass is still unclear, but it is probably of enzymatic origin, including CYP2D6 and CYP3A4 in liver metabolism. Finally, BBR is also the substrate of the efflux pump P-glycoprotein (P-gp). Therefore in recent years alternative approaches have been studied to increase the bioavailability of BBR, using permeability enhancers (sodium caprate, sodium deoxycholate, chitosan), P-gp inhibitors (silymarin), or modified release dosage forms (nanoemulsions, micelles, liposomes, nanoparticles), with quite satisfactory results.
Efficacy. The lipid-lowering efficacy of BBR has been confirmed by a recent meta-analysis that included 27 clinical studies with 2569 participants. The effects of berberine on lipids were: LDL-C, À0.65 mmol/L (95%CI, À0.75 to À0.56; P ¼ 0.00001; 25.14 mg/dL); TGs, À0.39 mmol/L (95%CI, À0.59 to À0.19; P ¼ 0.0001; 34.5 mg/dL); and HDL-C, 0.07 mmol/L (95%CI, 0.04-0.10; P ¼ 0.00001; 2.71 mg/dL). These effects seem to be additive to those of statins and associated with a positive impact on glucose metabolism and blood pressure as well. 137 A recent study enrolled 130 patients undergoing PCI who were randomized to 2 groups and treated with 600 mg/day of BBR or placebo in addition to standard therapies. The BBR group showed a marked reduction in TGs (26% BBR vs 13% control; the difference did not reach statistical significance due to large interindividual variations) and LDL-C (24% BBR vs 17% control; P < 0.001) compared with the control group. In addition, both groups showed a reduction in the levels of interleukin 6 (IL-6) and monocyte chemoattractant protein-1 (MCP-1) (P < 0.05 for each), as well as hs-CRP, intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and matrix metallopeptidase 9 (MMP-9) (P < 0.001 for all) compared with baseline. The levels of MMP-9, ICAM-1, and VCAM-1 after 1 month were significantly reduced to a greater extent in the BBR group compared with the control and baseline (P < 0.05). 138 In summary, the use of BBR at doses ranging between 500 mg and 1 500 mg has proved to be effective in lipid lowering and relatively safe both in primary and secondary prevention. Compared with nutraceuticals with a statin-similar mechanism of action, BBR has a greater effect in the reduction of triglyceridemia, partly related to its positive effect on insulin resistance. 139 Its use can therefore be recommended, especially in patients intolerant to statins with mild hypercholesterolemia and in patients with MetS.
Safety. Based on the abovementioned data, side effects are mild to moderate, mostly gastrointestinal (diarrhea, constipation, abdominal distension), and comparable with those in the control groups. 136 No significant differences were detected in the levels of aspartate transaminase (AST), alanine transaminase (ALT), and creatinine in comparison with the control group. 137 
Green tea extracts
Mechanism of action. Some available RCTs on green tea suggest that its consumption could be protective against CHD and CVD. 140 Green tea is particularly rich in antioxidants such as polyphenols (up to 35% of dried weight) that are well-known cardioprotective compounds. The major fraction of polyphenols in green tea is catechins, structurally flavan-3-ols. The most important one is the epigallocatechin-3-gallate (EGCG), known for its antioxidant and cardioprotective properties. It is possible that beyond the antioxidant effects derived from polyphenols and the reduction of lipid peroxidation, green tea interferes with micellar solubilization and absorption of cholesterol. Green tea is an activator of AMPK (stimulating lipogenesis) and an HMG-CoA reductase inhibitor. Tea catechins have been reported to have an inhibitory effect on the ileal apical sodium-dependent bile acid transporter (reducing reabsorption of bile acids) to enhance the hepatic LDL-R expression and the biliary excretion of cholesterol. 141, 142 Efficacy. A meta-analysis of 20 RCTs and 1536 participants showed a reduction of LDL-C (mean difference, À0.19 mmol/L [7.35 mg/dL]; 95%CI, À0.3 to À0.09; P ¼ 0.0004). The lipid-lowering effects of green tea were found to be greater in RCTs with longer duration. Moreover, green tea extract exerts a mild but significant antihypertensive effect. The tested daily doses ranged from 250 mg to 1200 mg of green tea extract or from 170 mg to 850 mg of EGCG. 143 Moreover, green tea is associated with an improvement in FMD 144 and pulse wave velocity (PWV), 145 effect on hs-CRP levels. 146 Therefore, overall the consumption of green tea might be associated with a decreased risk of CVD morbidity and mortality. 147 There are also no data on its influence on TGs and HDL-C.
Safety. Usually the consumption of green tea is well tolerated; however, in some cases, rash, transient elevation of blood pressure, and mild gastrointestinal disorders may occur. Moreover, high doses of green tea can cause a deficiency of iron and folate due to its capacity to bind and reduce their intestinal absorption. Therefore, particular attention should be given to green tea consumption during pregnancy. 143
Soy and lupin proteins
Mechanism of action. Preclinical and clinical evidence supports the positive effects of soy and lupin proteins on the lipid profile. Generally, it is believed that bioactive peptides present in soy and lupin (such as conglutingamma) may be responsible for the lipid-lowering effect of these legumes. 148 However, the isoflavones could contribute to this effect as well. 149 The cholesterol-lowering mechanisms proposed for soy and lupin seem to be numerous but are still unclear, including the downregulation of the expression of the hepatic transcription factor of sterol regulatory element binding protein (SREBP-1; via PI3K/Akt/GSK3b pathways, with decreased hepatic lipoprotein secretion and cholesterol content), the regulation of SREBP-2 (with increased clearance of cholesterol from the blood), the reduction of cholesterol synthesis, the increase of ApoB receptor activity, and the increase of the fecal excretion of bile salts. [150] [151] [152] [153] Efficacy. Several meta-analyses of RCTs have underlined the cholesterol-lowering properties of soy. In particular, a recent one that included 35 RCTs and 2670 participants concluded that soy proteins (in particular B-conglycinin globulin) have a cholesterollowering effect, with a mean reduction in LDL-C of 3% (À0.12 mmol/L/4.6 mg/dL), TC of 2% (À0.14 mmol/L/5.4 mg/dL), and TGs of 4% (À0.06 mmol/L/ 5.3 mg/dL) and are able to increase HDL-C by 3% (þ0.04 mmol/L/1.6 mg/dL), the effect being proportional to the baseline LDL-C level. 154 The mean tested dose was 30 g/day.
If isoflavones seem not to add significantly to the lipid-lowering effect of soy proteins, they seem to have direct positive effects on endothelial function 155 and arterial stiffness. 156 Yellow lupin (Lupinus luteus) is composed of proteins (30%-35%), fibers (30%), carbohydrates (3%-10%), and fat (6%, of which 81% is unsaturated); in addition, there are both macroelements (including phosphorus, calcium, and magnesium) and microelements (including zinc, copper, chromium, and cobalt). 157 One aspect that differentiates lupin from other legumes is the absence of phytoestrogens, low sodium content, and low glycemic index. In a randomized cross-over study, 33 hypercholesterolemic participants (TC > 6.6 mmol/ L/255 mg/dL) were treated for 8 weeks with 25 g/day of lupin protein isolate (LPI) followed by 4 weeks of washout and 8 weeks of treatment with milk protein isolate (MPI). Compared with baseline, a significant reduction of LDL-C was already observed in both groups after 4 weeks (À12%; P < 0.008). In the LPI group, the levels of HDL-C increased significantly (P < 0.036) and the LDL/HDL ratio decreased (P ¼ 0.003), compared with the MPI group. 158 These results were confirmed by the same author in the next randomized, controlled, double-blind, 3-phase crossover trial, which included 72 patients with hypercholesterolemia treated for 28 days with LPI, MPI, and milk proteins containing 1.6 g/d of arginine (MPA). In addition to reduced LDL-C levels (in MPA and LPI groups), the LPI group showed an improvement in the levels of homocysteine (compared with the MPI and MPA groups), uric acid, and TGs. 159 The cholesterol-lowering properties of lupin were also highlighted in a third RCT, which showed a reduction of LDL-C (À12%) comparable with the studies described previously. 160 It is also worth mentioning that exposure to isoflavone-containing soy products modestly, but significantly, improved endothelial function, as demonstrated in a meta-analysis of 17 RCTs. 155 In conclusion, the intake of soy and lupin represents a potential relatively weak adjuvant therapy in the treatment of hypercholesterolemia, especially in individuals with moderate cholesterol levels.
Safety. The chronic use of a high quantity of soy products containing isoflavones could interfere with thyroid function and fertility. Furthermore, soybean and its derivatives contain high amounts of phytic acid, which reduces the absorption of minerals such as calcium, magnesium, copper, iron, and zinc. Lupin has shown a good safety profile, causing no severe side effects, and those which occurred were mostly gastrointestinal. The large amount of vegetable proteins that have to be taken in order to obtain a significant LDL-C reduction could decrease patient compliance in the long term and should be accompanied by an attentive balance of the other dietary sources of proteins.
OTHER NUTRACEUTICALS WITH MIXED MECHANISMS OF ACTION
Polyunsaturated n-3 fatty acids n-3 fatty acids are polyunsaturated fatty acids (PUFAs) that contain a double bond in position 3 at the end of the carbon chain. Natural sources of n-3 are present in both animal (fish, krill, egg, squid) and plant (algae, flaxseed, walnut, edible seeds, clary sage, seed) sources. 161 In recent years the EFSA, the AHA, and the Food Standards of Australia and New Zealand (FSANZ) have recognized n-3 fatty acids as preventive nutraceuticals for CVD. 27 The EFSA established a claim in 2010 indicating that the intake of at least 2 g/day of docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) has the ability to maintain normal blood TG levels. 162, 163 The AHA has indicated doses from 2 g/day to 4 g/day of EPA/DHA to reduce TG levels by 25%-30%. 164 All of these guidelines agree about the high safety of PUFAs, despite the relatively frequent fishy aftertaste and occasional abdominal discomfort.
Mechanism of action. The mechanisms through which n-3 s reduce TGs are the reduction of synthesis of hepatic very-low-density lipoprotein (VLDL), the reduction of available substrate for the synthesis of new TGs (n-3 s are false substrates), the reduction of the activity of TG-synthesizing enzymes (diacylglycerol acyltransferase or phosphatidic acid phosphohydrolase), the increase of b-oxidation of fatty acids, the reduction of the endogenous synthesis of fatty acids, and the increase of synthesis of phospholipids. 165 Efficacy. The EFSA health claims and the statement of the AHA are supported by a large number of RCTs.
The meta-analysis of Eslick et al. included 47 RCTs with 16 511 participants with hypercholesterolemia to assess the effects of the average daily dose of 3.25 g of EPA/DHA for 24 weeks. The results showed a significant reduction in TGs of 14% (À0.34 mmol/L [30.12 mg/dL]; 95%CI, À0.41 to À0.27). In addition, there was a small, insignificant reduction of LDL-C of 0.06 mmol/L (2.3 mg/dL), but no differences in HDL-C. 166 These results were confirmed in normolipidemic and borderline patients in the meta-analysis by Leslie et al., which included 2270 individuals with optimal lipid or suboptimal TG profiles (TGs < 2 mmol/L [177 mg/dL]). In studies that used > 4 g/day of n-3 s, TGs were reduced by 9%-26%, whereas a reduction of 4%-51% was found with doses from 1 g/day to 5 g/day of n-3 s. 167 A dose-dependent effect of n-3 s was also observed by Di Stasi et al., 168 with additional benefits obtainable for lipid profile when supplementation with n-3 s was raised as high as 4.9 g/day. It was also observed that the administration of EPA or DHA individually gave comparable effects in the reduction of TGs, but not other lipid parameters; in fact, DHA showed a very modest reduction of LDL-C by 5% and slightly increased HDL-C, whereas EPA produced no significant changes. 169, 170 Polyunsaturated fatty acids might also be associated with an improvement of FMD and PWV and, with larger dosages, with positive effects on inflammatory diseases and mood. 171 Moreover, in the large, long-term Gruppo Italiano per lo Studio della Sopravvivenza nell' Infarto miocardico (GISSI) Prevenzione trial, which involved 11 324 patients surviving recent MI, supplementation with 1 g of EPA/DHA significantly reduced the risk of CV death. 172 A rich source of n-3 PUFAs is krill (Euphausia superba), a small crustacean that lives in the Antarctic Ocean and contains many types of long-chain PUFAs. The n-3 present in krill oil (EPA plus DHA) appears to be better absorbed in the gastrointestinal tract than that found in fish oil: this is possible because of phosphatidylcholine (the main phospholipid present in krill [40%], which binds EPA and DHA), which confers greater stability to fatty acids. In addition, krill oil is rich in antioxidants, including vitamin E and astaxanthin. 173 Therefore, at the same dose, krill oil appears to be more effective than fish oil in the adjustment of lipid profile. Ulven et al. 174 reported that the effects on the reduction of TGs of a dose of 543 mg of DHA and EPA contained in krill oil are comparable with doses of 2.66 g of EPA and DHA present in fish oil. Similar data were obtained by Cicero et al. 175 In the most recent meta-analysis of 7 RCTs with 662 participants, Ursoniu et al. 176 found a significant reduction in plasma concentrations of LDL-C (À15.52 mg/dL [0.4 mmol/L]; 95%CI, À28.43 to À2.61; P ¼ 0.018) and TGs (À14.03 mg/dL [0.16 mmol/L]; 95%CI, À21.38 to À6.67; P < 0.001) and significant elevation in plasma concentrations of HDL-C (6.65 mg/dL [0.17 mmol/L]; 95%CI, 2.30-10.99; P ¼ 0.003) following supplementation with krill oil. Controversial results were obtained with alphalinolenic acid (ALA), an n-3 fatty acid found in many vegetable oils (such as olive and flaxseed oil). Nevertheless, a rich source of ALA, the flaxseed (Linum usitatissimum, ALA ¼ 50%-62% of flaxseed oil or 22% of whole flaxseed), an oilseed crop grown on all continents, showed lipid-lowering activity regarding LDL-C (À0.08 mmol/L). This effect may be explained by the other components of flaxseed, including lignans (0.2-13.3 mg/g of flaxseed) and soluble fibers (25% of total weight), that could enhance the reduction of total cholesterol. The cholesterol-lowering effects were more significant in females (in particular in postmenopausal women) and in individuals with high cholesterol levels at baseline. 177 Flaxseed seems also to exert a mild but significant antihypertensive effect. 178 The available data suggest that the consumption of flaxseed is safe and well tolerated. Another vegetal source of essential fatty acids is sesame. A recent meta-analysis of RCTs showed that sesame fractions intake is associated with a significant TG reduction (À0.24 mmol/L [21.3 mg/ dL]; 95% CI, À0.32 to À0.15; P < 0.001), whereas no changes occurred with LDL-C or HDL-C levels. 179 In conclusion, n-3 EPA and DHA represent a valid nutraceutical to reduce TGs in the blood (by 18%-25%), whereas their effects on LDL-C and HDL-C are clinically insignificant. However, it has to be stressed that CVD outcome studies with n-3 s have produced inconsistent results, and their clinical efficacy appears to be related to nonlipid effects. It especially needs be noted that doses < 2-4 g/day, such as a low-dose supplementation of a margarine with n-3 PUFAs (400 mg/d of EPA plus DHA) or ALA (2 g/d) do not significantly reduce TG levels, as was confirmed in an RCT involving 4837 postmyocardial infarction patients. Such supplementation also did not reduce the rate of major CVD events. 180 A relatively recent meta-analysis that included data from 63 030 patients from 20 clinical trials showed that treatment with n-3 s did not have an impact on a composite CVD endpoint or total mortality but was associated with a significantly decreased rate of vascular death. 181 Safety. No serious side effects have been reported; most of them have been defined as mild gastrointestinal issues. 167 
Gamma-oryzanol
Mechanism of action. Another nutraceutical with a potential effect on lipid profile is gamma-oryzanol from rice bran oil. 182 Gamma-oryzanol is a mix of triterpene alcohol and sterol ferulates with lipid-lowering actions by the inhibition of HMG-CoA reductase and the reduction of intestinal cholesterol absorption. 183 To date in Korea at least 16 varieties of rice bran oil, containing different percentages of gamma-oryzanol (26.7-61.6 mg/100 g), have been identified. 184 Efficacy. The lipid-lowering effects of this nutraceutical have been shown in in vitro and in vivo studies (in animals and humans); however, the dosages to be used in clinical practice and impact of gamma-oryzanol on vascular health remain unclear. 182 A recent meta-analysis of 11 RCTs showed that rice bran oil consumption resulted in a significant decrease in concentrations of LDL-C (À0.18 mmol/L [7 mg/dL], 95%CI, À0.26 to À0.09; P < 0.001). The increase in HDL-C levels was considerable only in men (0.17 mmol/L [6.6 mg/dL]; 95%CI, 0.06-0.28; P ¼ 0.002). 185 Safety. Overall, no side effects have been registered with rice bran oil consumption. 185 Spirulina Mechanism of action. Spirulina (Arthrospira platensis) is a filamentous microalga with known lipid-lowering effects but with an unclear mechanism of action. 186 Spirulina contains high amounts of antioxidants such as beta-carotene, phycocyanin, microelements (potassium, sodium, calcium, magnesium, iron, zinc), vitamins (tocopherols), amino acids, and PUFAs. C-phycocyanin, a particular essential pigment of spirulina, contains a phycocyanobilin, which can activate atheroprotective heme oxygenase-1 (HMOX-1), a key enzyme in the heme catabolic pathway in endothelial cells. Moreover, phycocyanin has proven antioxidant, anti-inflammatory, and radical-scavenging properties. 187 Efficacy. According to experimental studies in alloxaninjured mice, phycocyanin decreases TC and TG levels in serum, increases the hepatic glycogen level, and maintains glucokinase expression in the liver. A recent meta-analysis that included 7 clinical trials to assess the effect of spirulina supplementation on plasma lipid concentrations showed the lipid-lowering efficacy of spirulina, with a reduction of LDL-C by À1.07 mmol/L (95%CI, À1.57 to À0.57; P < 0.001; 41.32 mg/dL), TC by 1.21 mmol/L (95%CI, À1.74 to À0.68; P < 0.001; 46.76 mg/dL), and TGs by À0.5 mmol/L (95%CI, À0.57 to À0.43; P < 0.001; 44.23 mg/dL) and an increase of HDL-C of þ0.16 mmol/L (95%CI, 0.06-0.25; P ¼ 0.001; 6.06 mg/dL). 187 Safety. Spirulina is considered to be one of the most healing and prophylactic ingredients of nutrition in the 21st century due to its nutrient profile, lack of toxicity, and therapeutic effects. According to the available data, it seems to be very well tolerated.
Curcumin
Mechanism of action. Curcumin is the major phenolic compound present in the spice turmeric (in the rhizome of Curcuma longa, curcuminoids constitute approximately 5% of the weight) and is associated with different properties, including lowering plasma cholesterol and having antioxidant and anti-inflammatory effects. 188 Other polyphenolic molecules belonging to the class of curcuminoids are demethoxycurcumin and bisdemethoxycurcumin. As reported in recent metaanalyses of RCTs, curcuminoids showed an increase in serum activities of superoxide dismutase (P ¼ 0.0007) and catalase (P ¼ 0.005) and glutathione concentrations (P ¼ 0.01) and a reduction in serum lipid peroxides (P ¼ 0.008) 189 and TNF-a. 190 The lipid-lowering mechanisms of action of curcuminoids are unclear; nevertheless, it seems that curcumin inhibits the expression of the NPC1L1 transporter via the SREBP2 transcription factor 191 and that it increases the efflux of cholesterol via expression of ABCA1 and activation of AMPK-SIRT1-LXRa signaling in THP-macrophage-derived foam cells. 192 Furthermore, curcumin enhances the number of LDL-R and promotes LDL particle uptake through downregulation of the expression of PCSK9. 193 In addition, epigenetic modulators such as microRNAs have emerged as novel targets of curcumin. 194 Efficacy. Nevertheless, the results of RCTs regarding the effects of curcumin on lipid profile are still inconsistent; a meta-analysis by Sahebkar 195 showed no significant effects on LDL-C, HDL-C, or TGs when considering heterogeneous populations. However, recently some available trials have provided more positive data. In a study that included MetS patients, treatment with 1 g/ day of curcuminoids as an add-on to the standard therapy resulted in a significant reduction of LDL-C (À0.78 mmol/L [30 mg/dL]; P < 0.001), TGs (À0.2 mmol/L [17.7 mg/dL]; P ¼ 0.006), and Lp(a) (À0.286 mmol/L [8 mg/dL]; P < 0.001) and an elevation of HDL-C (þ0.18 mmol/L [7 mg/dL]; P ¼ 0.003). 196 These data have since been confirmed in a further trial carried out on 100 MetS patients 197 and in another one with 80 NAFLD patients. 198 In recent RCTs, supplementation with curcumin (1 g/d) was associated with a reduction of serum uric acid (P < 0.001), increase of adiponectin (þ76.78%; P ¼ 0.033) levels, and reduction of leptin (À26.49%; P ¼ 0.238). 199 All these effects seem to be related to the main metabolic effect of curcumin, which is an improvement of insulin resistance. 200 Finally curcumin consumption is also associated with an improvement in FMD 201 and PWV. 202 Safety. Curcumin's safety profile is good and well documented. Nevertheless, a major problem is its oral bioavailability: curcumin has low solubility in water, and it is a substrate of rapid metabolism. New strategies of release, such as phytosomal complexation with phosphatidylcholine, coadministration of piperine, using turmeric oleoresin, reducing particle size, and changing the formulation (nanoemulsion, solid lipid nanoparticle, microencapsulation), have been studied and tested; however, in vivo data of these new formulations are lacking. 203 
L-carnitine
Mechanism of action. Carnitine is a hydrophilic quaternary amine that plays a number of essential roles in metabolism with the main function being the transport of long-chain fatty acids from the cytosol to the mitochondrial matrix for b-oxidation. 204 Efficacy. L-carnitine has no effect on LDL-C levels, but a meta-analysis of 7 RCTs that included data from 375 patients showed a significant reduction of Lp(a) levels following L-carnitine supplementation (À0.31 mmol/L [8.82 mg/dL], 95%CI, À0.36 to À0.27, P < 0.001). 205 Moreover, L-carnitine seems to have a positive impact on body weight management. 206 In the most recent meta-analysis of 10 RCTs with 925 patients, Mazidi et al. showed significant reduction of serum CRP and TNF-a concentrations following L-carnitine administration (À0.60 mg/L [5.71 nmol/L], 95%CI, À0.87 to À0.32; and À0.36 pg/dl; 95%CI, À0.56 to À0.15, respectively). 207 Safety. No safety concerns have been raised, but reliable safety data are still lacking.
Artichoke (Cynara scolymus, Cynara cardunculus)
Mechanism of action. According to some preclinical and clinical investigations, artichoke leaf extract (ALE) has potential hypolipidemic and hepatoprotective effects. The beneficial effects of artichoke can be attributed to its antioxidant action. The main substances are mono-and dicaffeoylquinic acid (cynarin and chlorogenic acid), caffeic acid (1%), volatile sesquiterpene, and flavonoids (1%), which include the glycosides luteolin-7-beta-rutinoside (scolymoside), luteolin-7beta-D-glucoside, and luteolin-4-beta-D-glucoside. 208, 209 The lipid-lowering mechanisms of artichoke seem to be essentially 2: the interaction of luteolin with the HMG-CoA reductase enzyme and the pathways of regulation in the liver of sterol regulatory elementbinding proteins (SREBPs) (paradoxically elevated in patients with nonalcoholic steatohepatitis ) and ACAT. 210 Efficacy. An RCT (75 patients treated for 12 wk with 1 280 mg/d of ALE or placebo) showed a mean reduction of TC by 4.2% compared with baseline and an increasing trend of TC levels in the placebo group. The total difference between the 2 groups was statistically significant (P ¼ 0.0025). No significant difference between groups was observed for LDL-C, HDL-C, or TG levels. 211 A second RCT (143 patients treated with 1 800 mg/d of ALE for 6 wk) showed a mean reduction of TC of 18.5% compared with 8.6% in the placebo group -the difference between the 2 groups was statistically significant (P < 0.00001). Moreover, the levels of LDL-C were also significantly decreased in the ALE group (mean, À1.26 mmol/L [48.7 mg/dL]) compared with the placebo group (mean, À0.33 mmol/L [12.8 mg/ dL]; P < 0.00001). No differences were observed for other lipid parameters. 212 The third study (44 patients treated with 1 920 mg/d of ALE for 12 wk) showed no significant differences in the lipid profile at the end of the treatment. However, according to a subgroup analysis, patients treated with ALE who had at baseline TC > 230 mg/dL showed a significant reduction of TC when compared with those treated with placebo (P ¼ 0.0015). 213 In a recent RCT, 60 patients moderately hyperlipidemic and hypercholesterolemic with nonalcoholic steatohepatitis were treated with 2 700 mg/day of ALE (6 tablets) or placebo for 2 consecutive months. The results showed a significant reduction of LDL-C by 11.5% (P ¼ 0.039) and TGs by 20.1% (P ¼ 0.011) compared with baseline. The most recent meta-analysis of 9 RCTs with 702 participants suggested a significant decrease in plasma concentrations of TC (weighted mean difference [WMD], À17.6 mg/dL [0.46 mmol/L], 95%CI, À22.0 to À13.3; P < 0.001), LDL-C (WMD, À14.9 mg/dL [0.39 mmol/L]; 95%CI, À20.4 to À9.5; P ¼ 0.011); and triglycerides (WMD, À9.2 mg/dL [0.1 mmol/L]; 95%CI, À16.2 to À2.1; P ¼ 0.011). 214 . In addition, ALE showed pleiotropic activities in the improvement of certain liver enzymes such as AST and ALT (P < 0.001), blood sugar (P ¼ 0.029), and systolic blood pressure (P ¼ 0.004) 210 Safety. In all studies published to date, no serious side effects have been detected, confirming the good tolerability and safety of ALE in the short/medium term. What is more, ALE exerts a hepatoprotective effect and might be useful in statin-intolerant patients with elevated ALT levels. In some cases, there have been minor and transient gastrointestinal effects. Long-term safety studies are not available yet. In conclusion, ALE could represent an adjuvant in the regulation of lipid profile and liver levels of AST and ALT; however, the available clinical data are still preliminary. Studies on vascular outcomes such as arterial stiffness and endothelial function are also needed. Efficacy. Data from clinical trials are, however, disappointing, showing minimal effects of vitamin E on lipid pattern. 216 On the other hand, vitamin E has shown a preventive action on CV risk. At doses between 50 mg and 200 mg, it showed an improvement of endothelial function (reducing the serum levels of hs-CRP, advanced glycation end products, metalloproteinases, and cell adhesion molecules) and arterial stiffness (improving PWV, pulse volume [PV], and the augmentation index). 217, 218 Clinical studies are needed to finally clarify the conflicting results in the literature, the dosages (100 mg of tocotrienols are different than 100 mg of vitamin E and 100 mg of tocopherols), and vitamin E components, which have greater lipid-lowering efficacy. Even if vitamin E seems not to be an effective lipid-lowering treatment, its supplementation seems to be associated with reduced risk of fatal myocardial infarction. 219 Safety. In humans, doses of tocotrienols up to 1 000 mg/ day have been reported as safe. 220 Anthocyanins Mechanism of action. Anthocyanins are flavonoid pigments found in leaves, stems, roots, flowers, fruits, and vegetables with dark color such as blueberries, black rice, purple cabbage, raspberries, purple grapes, and cherries. Among the biological activities exerted by anthocyanins, clinical trials have demonstrated particular antioxidant, anti-inflammatory, and lipid-lowering effects. 221 Efficacy. In 58 diabetic patients, 320 mg/day of anthocyanins for 24 weeks significantly decreased LDL-C (À7.9%; P < 0.05), TGs (À23%; P < 0.01), ApoB48 (À16.5%; P < 0.05), and apoCIII (À11%; P < 0.01) and increased HDL-C (þ19.4%; P < 0.05) compared with placebo. Moreover, the anthocyanin group showed an improvement of fasting plasma glucose (À8.5%; P < 0.05), homeostasis model assessment (HOMA) for insulin resistance index (P < 0.05) and adiponectin concentrations (þ23.4%; P < 0.01). 222 In addition to lipidlowering effects, anthocyanins are potent antioxidants, reducing the oxidative stress and inflammation; in humans, maqui berry extract significantly decreased lipid peroxidation, urinary F2-isoprostanes, and inflammatory mediators. 223 Epidemiological data suggest that higher dietary intakes of anthocyanins are associated with lower carotid-femoral PWV and carotid intimamedia thickness. 224 Safety. Anthocyanins are well tolerated without side effects at dosages 640 mg/day. Further studies are needed to assess the clinical efficacy of anthocyanins in different kinds of populations and to evaluate their vascular effects. Moreover, it will also be important to investigate the bioavailability of these compounds and the efficacy and safety of their metabolites. In fact, it is well known that the bioavailability of anthocyanins is low and they are rapidly biotransformed into derivates of phenolic acid. 225 
Silymarin (Silybum marianum)
Mechanism of action. Silymarin is a complex of flavonolignans of the fruit Silybum marianum containing silybin, isosilybin, silydianin, and silychristin, 4 polyphenolic molecules with poor water solubility. It is known for its antioxidant and hepatoprotective properties and in recent years as an adjuvant in hyperlipoproteinemias. 226 Silymarin reduces lipid peroxidation of LDL by acting as a chain-breaking antioxidant by scavenging free radicals and being associated with enzyme complexes such as superoxide dismutase and glutathione.
Efficacy. There are preliminary studies suggesting a potential role of silymarin as a lipid-lowering agent; studies have shown an inhibitory effect of silybin on HMG-CoA reductase in vitro and an improved uptake of LDL by the liver and a reduction of hepatic cholesterol synthesis in vivo 227 Specific data on hypercholesterolemic patients are not available. In diabetic patients, silymarin improves fasting plasma glucose and HbA1c but not lipid parameters. 227 Safety. Silymarin has low bioavailability. Further investigations and combination studies are needed to improve the intestinal absorption of this molecule; for example, in complex with phosphatidylcholine, silybin increases its bioavailability 10-fold. Safety data are still lacking.
Conjugated linoleic acid
Mechanism of action. Conjugated linoleic acids (CLAs) are isomeric forms of linoleic acid derived prevalently from the fatty tissues and milk of ruminant animals. Conjugaged linoleic acid is both a trans fatty acid and a cis fatty acid. 228 Efficacy. In prospective observational studies, dietary linoleic acid intake is inversely associated with CHD risk in a dose-response manner. 229 In a recent systematic review and meta-analysis, CLA supplementation was associated with a significant decrease in LDL-C (mean difference, À0.22 mmol/L [8.5 mg/dL]; 95%CI, À0.36 to À0.08; P ¼ 0.002), whereas nonsignificant results were obtained for HDL-C and TGs. 230 The results of a small RCT suggest that CLA supplementation could impair endothelial function. 231 Safety. In 2008, the FDA categorized CLA as generally recognized as safe.
Other nutraceuticals
Other nutraceuticals commonly cited as improving cholesterol metabolism are resveratrol and Hibiscus sabdarrifa L. (sour tea), but their lipid-lowering effects are not substantiated by available data. 232, 233 However, sour tea could have a significant blood pressuredecreasing effect. 234 Astaxanthin, a powerful antioxidant carotenoid, is often cited as having a lipidlowering effect, but this effect is not supported by clinical evidence, whereas its supplementation is associated with a mild but significant improvement in fasting plasma glucose. 235 
NUTRACEUTICAL COMBINATIONS
Rational combinations of nutraceuticals with different lipid-lowering activities, particularly when associated with an appropriate lifestyle, should provide an alternative to drug treatment for patients in primary CVD prevention with mildly elevated LDL-C (especially for those who are not on target) and in some statinintolerant patients. 236 There are many nutraceuticals with significant lipid-lowering properties. Most of them are used in combination with a low dosage of other nutraceuticals, statins, and other lipid-lowering drugs because that allows the risk of side effects to be reduced and the efficacy to be improved (reducing the residual CV risk). 237 Moreover, natural products with different mechanisms of action can be associated to achieve a potential synergetic effect, acting on the absorption of lipids from the bowel and/or increasing their excretion (soluble fibers, glucomannan, plant sterols, probiotics), enhancing the hepatic uptake of cholesterol (berberine, soybean proteins), inducing LDL-C excretion (berberine, soy proteins, chlorogenic acid), inhibiting HMG-CoA reductase enzyme and limiting the hepatic synthesis of cholesterol (monacolins, policosanols, allicin, soybean proteins, bergamot), and reducing the oxidation of LDL and increasing thermogenesis and lipid metabolism (chlorogenic acid). 238 For the below combination therapies, no mechanism of action is described because that information has been presented in detail in the previous sections. Red yeast rice and policosanols
Efficacy. The association of RYR extract (340 mg containing 5 mg of MonK) and octacosanols (10 mg) was tested in 111 patients with moderate hypercholesterolemia, normal/border-line triglyceridemia, and low CVD risk (<20% according to the Framingham Risk Score). The reduction of LDL-C was 20%, and it was similar to that obtained with pravastatin at a dose of 20 mg/day, without any serious safety concerns. 239 The efficacy of the combination of RYR extract (200 mg, corresponding to 3 mg of MonK) with linear aliphatic alcohols (10 mg) was also evaluated in the treatment of primary moderate hypercholesterolemia with a placebocontrolled clinical trial on 240 patients with overall coronary risk <20% (Framingham Risk Score); after 4 months a significant reduction in LDL-C (À29%) and non-HDL-C (À26%; P < 0.001) was achieved. 240 The combination of RYR extract (200 mg, corresponding to 3 mg of MonK) with policosanol (10 mg) was also tested in a large, single-blind, randomized, multicenter study in 411 centers, comparing the effect of the nutraceutical association plus diet versus diet alone with a follow-up of 16 weeks. In 2 408 eligible participants (1 665 adults and 743 elderly), LDL-C was reduced by 21%, and HDL-C improved by 13%, without significant changes in TG levels. 241 Beneficial results were also obtained in 40 children with heterozygous familial hypercholesterolemia and familial combined hyperlipidemia, who received a dietary supplement containing RYR extract (200 mg, corresponding to 3 mg of monacolins) and policosanols (10 mg) for 8 weeks; the treatment was effective, safe, and well tolerated. 242 Safety. Based on the data from all above-mentioned studies, no serious safety concerns have been raised.
Red yeast rice, policosanols, and berberine
Efficacy. The association of the lipid-lowering properties of RYR (3 mg of MonK), policosanols (10 mg), and berberine (500 mg) is the most studied in RCTs and the only one for which meta-analyses of RCTs are available.
A recent meta-analysis of 14 RCTs that included data from 3159 participants showed that the RYRpolicosanol-berberine association improved the plasma level of LDL-C by À0.61 mmol/L (23.6 mg/dL; P < 0.001), HDL-C by 0.07 mmol/L (2.71 mg/dL; P < 0.001), TGs by À0.16 mmol/L (14.2 mg/ dL; (P < 0.001), and glucose by À0.14 mmol/L (2.52 mg/dL; P ¼ 0.010). Moreover, the improvement in both lipid and glucose profile appeared to be maintained in the long-term observation. 243 The improvement of lipid profile was not dependent on duration of supplementation or baseline lipid levels, whereas a greater glucose-lowering effect was found with higher baseline glucose levels and longer durations of supplementation. 244 Moreover, the efficacy of this nutraceutical combination was investigated in a recent clinical trial that involved 100 participants with low-grade systemic inflammation (hs-CRP levels > 2 mg/L) and normal-borderline cholesterol levels (LDL-C ¼ 100-160 mg/dL [2.5-4.1 mmol/L]). After 3 months of treatment, a reduction of LDL-C (À23%; P < 0.001) was reported; hs-CRP and endothelial microparticle levels were also significantly decreased (À41% and À16%, respectively). It was highlighted that LDL-C change was positively associated with hs-CRP (P ¼ 0.04) and endothelial microparticle changes (P < 0.001); hs-CRP and endothelial microparticle changes were also related to each other (P ¼ 0.005). Therefore, in addition to improving cholesterol profile, there is potential for this combination of nutraceuticals to attenuate the degree of systemic inflammation and endothelial injury in participants with low-grade systemic inflammation. 244 This combination has also been tested in adult and elderly patients previously intolerant to statins, 245, 246 and was well tolerated in 80% of cases. The genetic variants of LDLR and PCSK9 that could be related to variations in response to lipid-lowering effects of this supplement have also been investigated. Three polymorphisms in the 3 0 UTR region of LDLR and 2 in the 5 0 UTR region of PCSK9 were associated with response to the treatment. These results could explain the variability observed in the response among patients with moderate hypercholesterolemia, and they may be useful in identifying patients who could potentially benefit the most from this supplementation. 247 It was also observed that endothelial function and PWV were improved by the combination of RYR and berberine in dyslipidaemic patients. 248, 249 Safety. Based on the available data, no serious safety concerns have been raised. Red yeast rice and plant sterols
Efficacy. The association of plant sterols/stanols with certain lipid-lowering ingredients was demonstrated to strengthen cholesterol-lowering efficacy and add TGlowering effects. 250 A small cohort of hypercholesterolemic patients (n ¼ 18 participants) was assigned to the intake of a nutraceutical product containing RYR 1 200 mg (titration in MonK not reported) and phytosterols 1 250 mg per daily dose. The results showed a reduction of LDL-C of 33% (1.37 mmol/L [53 mg/dL]) after 6 weeks of treatment (P < 0.05). 251 . These results have been recently confirmed in a double-blind, placebo-controlled, randomized clinical trial evaluating the effect of phytosterols 800 mg, RYR (5 mg of MonK), and their association in 90 hypercholesterolemic participants. The group treated with the nutraceutical association experienced an LDL-C reduction of 27.0% and ApoB decrease of 19.0% (both P < 0.001). 252 Safety. In the available studies none of the participants reported any muscle pains, and no abnormal liver function tests were observed while taking this supplement. However, further studies with longer follow-up are necessary to conclusively confirm this.
Red yeast rice and artichoke
Efficacy. Red yeast rice and artichoke have been combined with other nutraceuticals in order to test their activity on lipid parameters and inflammation. Some available trials have been carried out on an association of RYR (166.67 mg; 0.4% MonK), sugar canederived policosanols (3.70 mg; 90% policosanols, 60% octacosanol), and ALE (200 mg; 5%-6% chlorogenic acid) to be taken as 3 tablets per day. In a double-blind, randomized, parallel, controlled study on 39 participants with moderate hypercholesterolemia, after 16 weeks of treatment, LDL-C was reduced by 21.4% (95%CI, À13.3 to À24.9%; P < 0.001), and TGs decreased by 12.2% (95%CI, À24.4 to À0.1%; P < 0.05). 253 In a 16-week, randomized, double-blind, placebo-controlled trial carried out on 100 participants, the authors observed a reduction of LDL-C by 14.3% (À0.57 mmol/ L [22 mg/dL]; 95%CI, À0.8 to À0.31), as well as TC, ApoB100, and ApoB100/ApoA-I ratio, without modifying safety parameters. 254 Doubling the daily dose seemed not to add additional benefits, although there were no safety concerns with the higher dosage. 255 The association of RYR (200 mg, containing 10 mg of MonK), ALE (500 mg), and banaba extract (50 mg) was evaluated in a double-blind, placebo-controlled, crossover designed trial in 30 adults with suboptimal LDL-C levels in primary prevention of CVD. Patients followed a period of 6 weeks of treatment with a nutraceutical or placebo, then 2 weeks of washout, and finally 6 weeks in crossover. After the active treatment, a significant improvement in LDL-C (À18.2%), non-HDL-C (À15%), glutamic oxaloacetic transaminase (À10%), glutamatepyruvate transaminase (À30.9%), and hs-CRP (À18.2%) versus placebo was observed. No changes were observed in the other investigated parameters in both groups. 256 Safety. Based on the available data, no serious safety concerns have been raised, but further studies with longer follow-up are necessary to conclusively confirm this.
Red yeast rice, policosanol, and silymarin
Efficacy. A double-blind, placebo-controlled trial evaluated the effects of a combination of RYR (334 mg, containing 10 mg of MonK), policosanol (30 mg), and silymarin (150 mg) compared with placebo on lipid profile, endothelial, and inflammatory parameters in 134 low-risk dyslipidemic patients. After 3 months of treatment, the nutraceutical supplement decreased LDL-C Not demonstrated compared with baseline (P ¼ 0.041) and placebo (P ¼ 0.037). Triglycerides were reduced by the active product (P ¼ 0.039) but not by the placebo, even though, in the group-to-group comparison, no significant difference was recorded (P ¼ 0.061). All tested inflammatory parameters (soluble intercellular adhesion molecule-1, soluble vascular cell adhesion molecule-1, soluble E-selectin, MMP-2, MMP-9, hs-CRP, IL-6, and TNF-a) were reduced by the nutraceutical combination. 257 Another research group tested the same combination in a group of 80 hypercholesterolemic participants in an 8-week randomized clinical trial. When compared with placebo, nutraceutical combination-treated patients experienced a more favorable percentage change in LDL-C (À23.3%), hs-CRP (À2.4%), and endothelial function (pulse volume displacement vs baseline, þ17%). No significant difference was observed with respect to effects on TGs, HDL-C, and safety parameters. 258 Safety. Further studies with a long follow-up are necessary to evaluate the safety issues for this combination.
Red yeast rice and antioxidants
Efficacy. A nutraceutical supplement composed of RYR (10 mg of MonK) and coenzyme Q10 (CoQ10; 30 mg) was tested in a double-blind, placebo-controlled, crossover, randomized clinical trial carried out on 25 healthy, mildly hypercholesterolemic participants. The treatment duration was 4 weeks. When compared with the placebo group, monacolins/CoQ10-treated patients experienced a more favorable percentage change in LDL-C (À21.99%; 95%CI, À26.63 to À17.36), non-HDL-C (À14.67%; 95%CI, À19.22 to À10.11), MMP-2 (À28.05%; 95%CI, À35.18 to À20.93), MMP-9 (À27.19%; 95%CI, À36.21 to À18.15), and hs-CRP (À23.77%; 95%CI, À30.54 to À17.01). No significant differences were observed with respect to TGs, HDL-C, and safety parameters. 259 The same combination was then evaluated in 40 moderately hypercholesterolemic participants with a double-blind, placebo-controlled, randomized clinical trial. After 6 months of active treatment, the results showed a more favorable percentage change in LDL-C (À26.3%; P < 0.05), endothelial reactivity (PV displacement, þ6.0%; P < 0.05), and arterial stiffness (PWV, À4.7%; P < 0.05). 260 Red yeast rice (10 mg of monacolins) has also been associated with a pool of antioxidants (100 mg of green tea dry extract, 20 mg of CoQ10, 2 mg of astaxanthin, 20 mg of resveratrol, and 50 mg of quercetin) and has been tested in a crossover, doubleblind, placebo-controlled RCT on 25 moderately hypercholesterolemic, pharmacologically untreated participants as primary prevention for CVD. After 4 weeks of the active treatment, patients experienced an improvement of cholesterol levels (LDL-C, À22.36%; non-HDL-C, À22.83%), hsCRP (À2.33%), and endothelial function (PV displacement after monacolin treatment, 18.59%). 261 Safety. Based on the available data, no serious safety concerns have been raised.
Berberine combined with bioactive lipid-lowering agents other than red yeast rice Efficacy. Berberis aristata extract (588 mg, containing 500 mg of berberine) was combined with chlorogenic acid (67 mg) and tocotrienols (143 mg) in a doubleblind, cross-over designed trial versus placebo in 40 overweight participants with mixed hyperlipidemia. After 8 weeks of treatment, a significant improvement in LDL-C (À24%), TGs (À19%), non-HDL-C (À22%), fasting insulin (À5%), and HOMA index (À10%) was observed. 262 Another double-blind, placebo-controlled, crossover RCT tested the efficacy of the administration of Berberis aristata (588 mg of extract containing 500 mg of berberine) with Silybum marianum (105 mg of extract) twice a day in 102 dyslipidemic patients. The results showed a reduction of LDL-C and TGs and an increase of HDL-C after the first 3 months of treatment; the lipid profile worsened after a 2-month washout period and improved again when the nutraceutical combination was reintroduced for a further 3 months. 263 Given the low lipid-lowering activity of components different from berberine, it is not clear whether the observed effects are related to berberine per se or not.
Safety. Based on the available data, no serious safety concerns have been raised, but further studies with a long follow-up are still necessary to confirm this.
Soy proteins and plant sterols
Efficacy. Low-dosed soy proteins and plant sterols have been demonstrated to have mild but additive cholesterol-lowering effects in humans. 264 The intake of soy proteins with plant sterols in patients with MetS and LDL-C ! 160 mg/dL (4.1 mmol/L) showed a significant (P < 0.05) improvement in LDL-C, non-HDL-C, cholesterol/HDL-C and TG/HDL-C ratios, ApoB, ApoB/ApoA-1 ratio, homocysteine, total LDL particle number, and large HDL particle number, in particular after 12 weeks of treatment. 265 Soy proteins (16.2 g/ 1000 kcal) and plant sterols (1.2 g/1000 kcal) were also combined with viscous fibers (8.3 g/1000 kcal) and almonds (16.6 g/1000 kcal) in the treatment of a small cohort of hypercholesterolemic participants; after their intake for 4 weeks, a reduction of LDL-C (35.0% 6 3.1%; P < 0.001) and the ratio of LDL-C to HDL-C (30.0% 6 3.5%; P < 0.001) was reported. 266 Safety. Based on the available data, no safety concerns have been raised, but further studies with a long followup are still necessary to confirm this.
DIFFERENT NUTRACEUTICAL COMBINATIONS SUPPORTED BY SINGLE RANDOMIZED CONTROLLED TRIALS
For these combined products, due to lack of enough data, it is not possible at this moment to suggest a final classification. The level of evidence might have been limited to "B" or "C" -expert opinion with the class of suggestion IIb waiting for confirmative trials.
Red yeast rice and n-3 polyunsaturated fatty acids
Efficacy. 
Psyllium and plant sterols
Efficacy. A nutraceutical supplement with psyllium (7.68 g) and plant sterols (2.6 g) was administered to a small cohort of patients (n ¼ 33 patients) with LDL-C levels between 2.58 (100 mg/dL) and 4.13 mmol/L (160 mg/dL) in a placebo-controlled clinical trial. Participants were treated for 4 weeks with the nutraceutical combination versus placebo, followed by a 3week washout period, and finally received the alternative treatment (placebo/nutraceutical) for another 4 weeks. The improvement in lipid profile included a reduction of LDL-C from 3.5 6 0.7 mmol/L (135 mg/ dL) to 3.1 6 0.8 mmol/L (120 mg/dL) after the intake of the nutraceutical product (P < 0.01). Moreover, this combination led to a reduction of plasma ApoB concentrations (P < 0.01). 269 Safety. No safety concerns have been noted. However, very limited data are available, and further studies are necessary.
Psyllium and n-3 polyunsaturated fatty acids
Efficacy. Plant sterols with n-3 fatty acids have synergistic lipid-lowering effects, as demonstrated in a 3-week, randomized, placebo-controlled clinical trial on 60 hyperlipidemic individuals. The participants were divided into 4 groups and received either sunola oil or n-3 long chain PUFA capsules (1.4 g/d) with or without phytosterols (2 g) or placebo. The combination of phytosterols and n-3 PUFAs reduced LDL-C by 12.5% (P ¼ 0.002) and TGs by 25.9% (P ¼ 0.005); moreover, it increased HDL-C (þ8.6%; P ¼ 0.04). 270 Safety. No safety concerns have been noted. However, very limited data are available, and further studies are necessary.
Garlic and n-3 polyunsaturated fatty acids
Efficacy. Garlic oil (500 mg) and fish oil (600 mg) were administered to a small sample of hypercholesterolemic patients (n ¼ 16 patients) for 2 months and compared with a control group (n ¼ 16 patients). The results showed an improvement of lipid parameters: LDL-C, À21%; TGs, À37%; VLDL, À36.7%; TC/HDL-C ratio, À23.4%; HDL-C, þ5.1%. 271 Safety. No safety concerns have been noted. However, very limited data are available, and further studies are necessary.
Gamma-oryzanol and n-3 polyunsaturated fatty acids
Efficacy. Pantethine, soybean plant sterols, green tea extract, delta-tocotrienol, and phytolens Efficacy. A clinical trial on 30 hyperlipidemic untreated patients showed a significant improvement in serum lipids using a nutraceutical product with a combination of pantethine (900 mg), soybean plant sterols (800 mg), green tea extract (600 mg containing 50% epigallocatechin gallate), gamma/delta tocotrienols from annatto seed (75 mg), and phytolens from lentil husks (5 mg). After 2 months of treatment, there was a significant reduction of LDL-C by 14% (P < 0.003), VLDL by 20% (P < 0.01), and sdLDL particles by 25% (types III and IV). 275 Safety. No safety concerns have been noted. However, very limited data are available, and further studies are necessary.
NUTRACEUTICALS COMBINED WITH PHARMACOLOGICAL THERAPY
Many available data, including that from the most recent studies with PCSK9 inhibitors, support the LDL-C concept that "lower is better." 76 Even knowing that statins are the drugs of choice in patients with high LDL-C levels and moderate-to-high CV risk, the use of high-intensity statins increases the side effects and therefore reduces therapy adherence and compliance. 277, 278 On the other side, even with good statin therapy tolerability, the LDL-C targeted levels might not be achieved for 30%-70% of patients (depending on the risk), even in the combination with ezetimibe for high-and very high-risk patients. 279 Many nutraceutical options are available either alone or in combination with statins to help reach recommended goals in a safe and tolerable way for most patients. 280 Clinical trials have found that many nutraceuticals have an additive effect to lipid-lowering drugs, allowing the statin doses to be reduced without diminishing the results in terms of TC and LDL-C reduction and significantly limiting adverse effects. 281 However, most of the combinations presented below have been tested only in a single study, and the obtained results have not been confirmed yet, so no recommendations can be made.
Statins and polyunsaturated fatty acids
Efficacy. The effect of PUFAs in statin-treated patients is simply additive in terms of dose-related TG reduction. 282, 283 Data from a long-term RCT support the concept that combining statins with n-3 fatty acids seems to further decrease CHD risk by 19% in primary prevention 284 and CHD mortality by 17% in secondary prevention. 285 Given the availability of data on CVD event risk reduction, the supplementation of PUFAs in statin-treated patients can be recommended, especially in hypertriglyceridemic and post-CHD patients.
Safety. No safety concerns have been noted. However, very limited data are available, and further studies are necessary.
Statins and soluble fibers
Efficacy. The lipid-lowering effects of psyllium (10 g/d) and lovastatin (20 mg/d), alone and in combination, were evaluated on 36 volunteers. After 4 weeks of treatment, the mean LDL-C and TG levels in the group receiving 20 mg of lovastatin plus 10 g of psyllium fell by 30.9% and 26.2% from baseline compared with 24.8% and 32.9% in the group receiving 20 mg of lovastatin and 3.6% and 10.9% in the group receiving 10 g of psyllium, respectively. 286 Another 12-week, blinded, placebo-controlled study tested the effects of 20 mg of simvastatin plus placebo, 10 mg of simvastatin plus placebo, or 10 mg of simvastatin plus 15 g of psyllium daily, enrolling 68 patients. After 8 weeks, the mean lowering of LDL-C (À63 mg/dL/À1.63 mmol/L; P ¼ 0.03) in the group receiving 20 mg of simvastatin plus placebo was the same as that in the group receiving 10 mg of simvastatin plus psyllium and was greater than that obtained with 10 mg of simvastatin plus placebo (55 mg/dL/1.42 mmol/L; P ¼ 0.03). Similar results were reported for ApoB and TC, whereas significant changes of TG or HDL-C levels were not observed. 287 In a further randomized, parallel-design clinical trial, patients with primary hypercholesterolemia (n ¼ 116) were assigned to receive a daily dose of 25 g of fiber (corresponding to 6 g of soluble fibers) plus 40 mg of rosuvastatin (n ¼ 28), 40 mg of rosuvastatin alone (n ¼ 30), 40 mg of simvastatin plus 10 mg of ezetimibe plus 25 g of fiber (n ¼ 28), or 40 mg of simvastatin plus 10 mg of ezetimibe (n ¼ 30) alone for 12 weeks. These therapies led to similar reductions in LDL-C and TC (P < 0.001 vs baseline), whereas no change was observed in HDL-C. Among patients treated with highly effective lipidlowering therapy, the intake of 25 g of fibers added favorable effects: a reduction of phytosterolemia, improvement in blood glucose (P ¼ 0.047), weight loss (P ¼ 0.04), and reduced body mass index (P ¼ 0.002). 288 Given the availability of data from different RCTs, the supplementation of fibers in statin-treated patients might be recommended, especially in patients with stipsis or irritable bowel disease. It remains to be clarified, however, whether the supplemented fibers interfere with other drugs administered by patients at high CVD risk.
Ezetimibe, red yeast rice, policosanol, and berberine
Efficacy. Ezetimibe and nutraceuticals have both been introduced, alone or in association, as alternative therapies for statin-intolerant patients and proved to be effective and well tolerated. A clinical trial evaluated the effects of a combination of nutraceuticals ( 289 Berberine (500 mg), red yeast rice (200 mg), and policosanol (10 mg) were also associated with ezetimibe (10 mg) in a study on 26 patients with primary hypercholesterolemia with a history of statin intolerance or refusing statin treatment. After 3 months of treatment, it was observed that this treatment was as effective as statins in moderate doses (LDL-C, À37%; TGs, À23%). 290 Safety. No safety concerns have been noted. However, very limited data are available, and further studies are necessary.
Ezetimibe or statins and berberine with silymarin
Efficacy. Berberis aristata (588 mg, containing 500 mg of berberine) and Silybum marianum (105 mg) extracts were administered twice a day to 45 patients diagnosed with type 2 diabetes with hypercholesterolemia and statin intolerance. The intake of berberine/silymarin with statins led to an improvement of lipid parameters (LDL-C, -15% and -28%, respectively, after 6 and 12 mo); this was also the case when added to ezetimibe (LDL-C, -20% and -33%, respectively, after 6 and 12 mo). In the control group, in which only berberine/ silymarin was administered, there was also a reduction of LDL-C (LDL-C, -17% and -26%, respectively, after 6 and 12 mo). Glycemic control improved in all groups. All reported side effects lasted a few days and did not lead to interruption of treatment. 291 Safety. No safety concerns have been noted. However, very limited data are available, and further studies are necessary.
Statins/ezetimibe and plant sterols
Efficacy. A randomized clinical trial with parallel arms was designed to evaluate the lipid-lowering effects of the addition of plant sterols to lipid-lowering drugs. Eighty-six participants were submitted to a 4-week runin period with 10 mg of atorvastatin (baseline), followed by another 4-week period in which participants received 40 mg of atorvastatin, 10 mg of ezetimibe, or a combination of both drugs (phase I); finally, capsules containing 2.0 g of plant sterols were added to previously assigned treatments for 4 weeks (phase II). Compared with baseline, 40 mg of atorvastatin showed a reduction of LDL-C (22%; P < 0.05) and increased b-sitosterol, campesterol/cholesterol, and b-sitosterol/cholesterol ratios (þ39%, þ47%, and þ32%, respectively; P < 0.05); 10 mg of ezetimibe reduced campesterol and campesterol/cholesterol ratio (67% and 70%, respectively; P < 0.05); and the combined therapy decreased LDL-C (38%; P < 0.05), campesterol, b-sitosterol, and campesterol/cholesterol ratio (54%, 40%, and 27%, respectively; P < 0.05). This study demonstrated that the addition of plant sterols further reduced LDL-C by approximately 6.5% in the atorvastatin therapy group and 5.0% and 4.0% in the combined therapy group (P < 0.05 for all). 292 Eleven hypercholesterolemic coronary patients on a low-fat, low-cholesterol baseline diet added simvastatin (20 mg/d) for 3 months and then dietary plant stanol ester margarine (2.25 g of stanols/d) for 8 weeks; afterwards, cholestyramine (8 g/d) was added for another 8 weeks. The results highlighted that simvastatin reduced LDL-C by 39% (P < 0.001), and additional stanol ester margarine reduced it by a further 13% (P < 0.05). The triple treatment led to a 67% reduction of LDL-C from baseline (P < 0.001), with all LDL-C values < 2.6 mmol/L, and a 15% increase of HDL-C (P < 0.01). It also increased the serum lathosterol/ cholesterol ratio (P < 0.01), thus showing upregulation of cholesterol synthesis, and increased the serum sitosterol ratio (P < 0.01). These results support the use of stanol ester with only moderate doses of statin and resin to control LDL-C levels in hypercholesterolemic patients. 293 Safety. No safety concerns have been noted. However, very limited data are available, and further studies are necessary.
Statins and tocotrienols
Efficacy. A clinical trial with 28 hypercholesterolemic participants was carried out to assess the efficacy of the tocotrienol-rich fraction of rice bran alone and in combination with lovastatin. The combination of the tocotrienol-rich fraction (50 mg) and lovastatin (10 mg) plus the AHA step-1 diet was demonstrated to significantly reduce LDL-C by 25% (P < 0.001), an additional 10% in comparison with statin therapy alone. 293 Safety. No safety concerns have been noted. However, very limited data are available, and further studies are necessary.
Statins and bergamot
Efficacy. The association of bergamot-derived polyphenolic fraction (1 000 mg/daily for 30 d) with rosuvastatin (10 mg/d for 30 d) was evaluated in a study that enrolled 77 patients with mixed hyperlipidemia. It was observed that the combined therapy significantly reduced LDL-C (À53%) compared with rosuvastatin alone, an effect that was nearly the same as the one produced by 20 mg of rosuvastatin. In addition, TGs were reduced by 36%, and HDL-C increased by 37%, an effect that was significantly higher when compared with the use of rosuvastatin alone. Moreover, a significant reduction of biomarkers used for detecting oxidative vascular damage was reported, suggesting antioxidant activity of bergamot in patients on statin therapy. 120 Safety. No safety concerns have been noted. However, very limited data are available, and further studies are necessary.
Statins and garlic
Efficacy. The therapeutic effect of the combination of black seed with garlic as a treatment for dyslipidemia was evaluated in a randomized, double-blind, placebo-controlled, 2-arms parallel study on 258 participants who met the Adult Treatment Panel III criteria for drug treatment of hyperlipidemia and dietary intervention. Patients who followed 8-week treatment with simvastatin (10 mg) plus placebo obtained a significant reduction in non-HDL-C (À10.8%), TGs (À6.9%), and LDL-C (À11.6%) (P 0.01) and an increase in HDL-C (þ10.4%; P ¼ 0.02). Patients who received simvastatin (10 mg) plus black seed (500 mg) and garlic (250 mg) for 8 weeks showed a greater improvement of lipid parameters: LDL-C, À29.4%; TGs, À20.1%; non-HDL-C, À27.4%; and HDL-C, þ21.4% (P ¼ 0.01). The higher (2.1-2.9 times) results obtained with simvastatin plus black seed and garlic as compared with the other group demonstrated the synergetic effect of this association of a nutraceutical combination with pharmacological treatment. 295 Safety. No safety concerns have been noted. However, very limited data are available, and further studies are necessary.
Statins and vitamin D
Efficacy. Low vitamin D status has been associated with hyperlipidemia. A double-blind, placebo-controlled trial was assessed on 56 hypercholesterolemic patients, who were randomly assigned to receive 200 IU/day of vitamin D (n ¼ 28) or a placebo (n ¼ 28) as an add-on to statin for 6 months. At the end of the treatment, participants who received vitamin D supplementation had an increased level of serum 25-hydroxyvitamin D concentrations compared with those who received placebo (þ16.3 6 11.4 compared with þ2.4 6 7.1 ng/mL; P < 0.001). Moreover, the differences in TC and TG levels between the statin plus vitamin D group and statin plus placebo group were significant: À0.57 mmol/L (95%CI, À0.83 to À0.32; P < 0.001; 22 mg/dL) and À0.32 mmol/L (95%CI, À0.55 to À0.09; P < 0.001; 28.3 mg/ dL), respectively. Moreover, in patients with 25-hydroxyvitamin D level < 30 ng/mL at baseline (n ¼ 43), serum TC and TG levels were further reduced by À0.74 6 0.31 mmol/L (28 mg/dL; P < 0.001) and À0.42 6 0.22 mmol/ L (37 mg/dL; P < 0.001), respectively. Therefore, the intake of vitamin D together with statin can be a useful tool in the management of hypercholesterolemic patients. 296 Taking into consideration that low serum vitamin D level seems to be associated with CVD risk and development of statin-related myopathy, the supplementation of vitamin D should always be considered in patients with low vitamin D levels. 297 Safety. No safety concerns have been noted. However, very limited data are available, and further studies are necessary.
CONCLUSION
A large number of nutraceuticals have been tested in clinical trials, demonstrating their lipid-lowering effects, with different levels of evidence. It is, however, important to once again emphasize that nutraceuticals cannot replace lipid-lowering therapy but might essentially help to optimize it (reducing CV residual risk). Taking into account the influence of some of the presented nutraceuticals on different lipid parameters, it seems that this therapy might be especially important to consider for patients with mixed dyslipidemia, especially atherogenic dyslipidemia in patients with diabetes and MetS; in patients with low-to-moderate hypercholesterolemia not on target; and in all patients with statin-associated side effects who cannot be treated with statins/suitable doses of statins and are at higher risk of CV events. 298 However, the main concern is still which lipidlowering effects of nutraceuticals are clinically relevant, which are maintained in the long term, and which might also be associated with an improvement in CVD risk. Combinations of lipid-lowering nutraceuticals could improve their safety (reducing the dosages of the single components), but their efficacy has been rarely tested in > 1 study/RCT, and some of the tested nutraceutical combinations contained underdosed components. On the other hand, both single components and some combinations (in particular, the combination of RYR, berberine, and policosanol) have proved to maintain their efficacy in the long term (years), have a positive impact on CVD risk factors other than LDL-C, and improve some markers of vascular aging (endothelial function, pulse wave velocity). Finally, some nutraceuticals have been shown to significantly improve the efficacy of standard pharmacological treatments. In this context, an evidence-based approach to the use of lipidlowering nutraceuticals could improve the quality of the treatment, including therapy adherence, and achievement of the LDL-C goal in clinical practice. However, it has to be clearly stressed that there are still no outcome studies proving that nutraceuticals can prevent CVD morbidity or mortality.
